[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 107
1. Alcalá-Galiano A, Borruel Nacenta S, Jiménez-Arranz S, Martín-Medina P: [Serous oligocystic adenoma of the pancreas]. Radiologia; 2007 Nov-Dec;49(6):427-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serous oligocystic adenoma of the pancreas].
  • [Transliterated title] Adenoma seroso oligoquístico del páncreas.
  • Serous oligocystic or macrocystic adenoma of the pancreas is a very uncommon morphological variant of what was classically termed microcystic adenoma of the pancreas.
  • This is a benign neoplasm; however, its radiological appearance mimicks that of potentially malignant mucinous neoplasms of the pancreas.
  • [MeSH-major] Adenoma / radiography. Pancreatic Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021674.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Mohan H, Garg S, Punia RP, Dalal A: Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature. JOP; 2007;8(4):453-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature.
  • CONTEXT: The presence of a combined serous cystadenoma and pancreatic endocrine neoplasm is a distinct clinicopathological entity rather than the incidental concurrence of two separate entities.
  • Imaging techniques showed an irregular mass having a mixed solid and cystic consistency, arising from the body of the pancreas and involving the lesser sac.
  • The diagnosis of combined microcystic adenoma and pancreatic endocrine neoplasm was made.
  • CONCLUSION: This case emphasizes the importance of careful gross examination, sampling and reporting of pancreatic tumors.
  • The coexistence of pancreatic endocrine neoplasms with potential malignant behavior may be overshadowed by obvious benign tumors such as a microcystic serous cystadenoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / complications. Cystadenoma, Serous / complications. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625299.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


3. Malur PR, Suranagi VV, Bannur HB, Kulgod S: Serous microcystic adenoma of the pancreas. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):408-10
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous microcystic adenoma of the pancreas.
  • Serous microcystic adenoma (SMA) is a rare benign neoplasm.
  • It accounts for 1-2% of all exocrine pancreatic tumors.
  • It is usually located in the body and the tail of the pancreas.
  • We present one such rare case of SMA occurring in the head of the pancreas, an infrequent location requiring a Whippel's resection.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679977.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. National Toxicology Program: Toxicology and carcinogenesis studies of 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser; 2010 Nov;(559):1-174

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the 53-week interim evaluation, three 4,600 g/kg rats had liver cholangiocarcinoma and one had hepatocellular adenoma.
  • At 2 years, there were significant treatment-related increases in the incidences of cholangiocarcinoma and hepatocellular adenoma.
  • At 2 years, there were marginally increased incidences of exocrine pancreatic adenoma or carcinoma in the 460, 1,000, and 4,600 g/kg core study groups.
  • Numerous nonneoplastic effects were seen in other organs including: adrenal cortical atrophy and cytoplasmic vacuolization, pancreatic acinar cell cytoplasmic vacuolization and arterial chronic active inflammation, follicular cell hypertrophy of the thyroid gland, inflammation and respiratory epithelial hyperplasia of the nose, and kidney pigmentation.
  • CONCLUSIONS: Under the conditions of this 2-year gavage study, there was clear evidence of carcinogenic activity of PCB 118 in female Harlan Sprague-Dawley rats based on increased incidences of neoplasms of the liver (cholangiocarcinoma, hepatocholangioma, and hepatocellular adenoma) and cystic keratinizing epithelioma of the lung.
  • Occurrences of squamous cell carcinoma of the uterus and acinar neoplasms of the pancreas may have been related to administration of PCB 118.
  • Administration of PCB 118 caused increased incidences of nonneoplastic lesions in the liver, lung, adrenal cortex, pancreas, thyroid gland, nose, and kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383778.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 31508-00-6 / 2,3',4,4',5-pentachlorobiphenyl; DFC2HB4I0K / Polychlorinated Biphenyls; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


5. Dietrich CF, Braden B, Hocke M, Ott M, Ignee A: Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound. J Cancer Res Clin Oncol; 2008 Jun;134(6):635-43
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound.
  • The role of CEUS in pancreatic disease is less obvious.
  • We prospectively evaluated CEUS for characterization of undetermined solid pancreatic lesions (gold standard histology).
  • PATIENTS AND METHODS: A total of 112 solitary undetermined pancreatic masses (70 ductal adenocarcinoma and 42 neoplastic nodules of other origin) were prospectively examined in patients without metastatic disease using transabdominal ultrasound.
  • Tumour enhancing features were analyzed in comparison to the surrounding pancreatic parenchyma in patients with adequate visualisation.
  • CONCLUSION: CEUS allows differential diagnosis of ductal adenocarcinoma and non-ductal adenocarcinoma (mainly neuroendocrine tumours and (microcystic) serous pancreatic adenoma) in the most of cases.
  • [MeSH-major] Abdomen / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma / ultrasonography. Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Endosonography. Female. Humans. Image Enhancement. Lymphoma / ultrasonography. Male. Middle Aged. Neuroendocrine Tumors / ultrasonography. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2008 Jun;134(6):723
  • (PMID = 17952469.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


6. Choi H, Kim S, Moon JH, Lee YH, Rhee Y, Kang ES, Ahn CW, Cha BS, Lee EJ, Kim KR, Lee HC, Jeong SY, Kim HJ, Lim SK: Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene. Yonsei Med J; 2008 Aug 30;49(4):655-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEN1 is characterized by the presence of functioning and nonfunctioning tumors or hyperplasia of the pituitary gland, parathyroid glands, and pancreatic islet cells.
  • Endoscopic ultrasonography demonstrated esophageal leiomyoma and pancreatic islet cell tumor.
  • This is the first case of MEN1 accompanied with multiple leiomyomas, parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal tumor.


7. Cui Y, Tian M, Zong M, Teng M, Chen Y, Lu J, Jiang J, Liu X, Han J: Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology; 2009;9(1-2):89-98
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma.
  • BACKGROUND: Dual expression of potential biomarkers in both benign and malignant pancreatic tumors was a major obstacle in the development of diagnostic biomarkers of early pancreatic cancer.
  • METHODS: To better understand the limitations of potential protein biomarkers in pancreatic cancer, we employed two-dimensional difference gel electrophoresis technology and tandem mass spectrometry to study protein expression profiles in pancreatic cancer tissues, benign pancreatic adenoma and normal adjacent pancreas.
  • RESULTS: 21 spots were overexpressed and 24 spots were downexpressed in pancreatic cancer compared with benign and normal adjacent tissues.
  • Our study demonstrated that three candidate pancreatic ductal adenocarcinoma biomarkers identified in previous studies, fructose-bisphosphate aldolase A, alpha-smooth muscle actin and vimentin, were also overexpressed in pancreatic cystadenoma, which might lower their further utility as biomarkers for pancreatic cancer.
  • Aflatoxin B(1) aldehyde reductase (AKR7A2) was confirmed to be only highly expressed in pancreatic cancer, not in normal adjacent pancreas and benign tumors.
  • CONCLUSIONS: The protein profile pattern of pancreatic cystadenoma was more similar to normal adjacent pancreas than pancreatic cancer.
  • We identified panels of the upregulated proteins in pancreatic cancer, which have not been reported in prior proteomic studies.
  • AKR7A2 may be a novel potential biomarker for pancreatic cancer.
  • [MeSH-major] Aldehyde Reductase / biosynthesis. Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / metabolism. Cystadenoma / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077459.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chaperonin 60; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human; 0 / Vimentin; 117896-08-9 / nucleophosmin; EC 1.1.1.- / aflatoxin B1 aldehyde reductase; EC 1.1.1.21 / Aldehyde Reductase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


8. Stern JR, Frankel WL, Ellison EC, Bloomston M: Solid serous microcystic adenoma of the pancreas. World J Surg Oncol; 2007;5:26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid serous microcystic adenoma of the pancreas.
  • BACKGROUND: Cystic neoplasms of the pancreas are less common than solid tumors, and portend a better prognosis.
  • They can be divided into serous and mucinous subtypes, with the former behaving less aggressively and generally considered benign.
  • Of the serous neoplasms, serous microcystic adenoma is the most common.
  • An extremely rare solid variant of serous microcystic adenoma lacking secretory capability has been described.
  • CASE PRESENTATION: We present a case of a 62 year-old man with a history of abdominal pain, who on CT scan was found to have a solid mass at the junction of the head and body of the pancreas.
  • The patient was offered resection for diagnosis and treatment, and subsequently underwent distal pancreatectomy and splenectomy.
  • Based on gross pathology, histology and immunohistochemistry, the mass was determined to be a solid serous microcystic adenoma.
  • CONCLUSION: Solid serous microcystic adenoma shows similar histologic and immunohistologic features to its classic cystic counterpart, but lacks any secretory functionality.
  • It appears to behave in a benign manner, and as such, surgical resection is curative for patients with this tumor.
  • Furthermore, until more cases of solid SMA are identified to further elucidate its natural history and improve the reliability of preoperative diagnosis, surgical resection of this solid pancreatic tumor should be considered standard therapy in order to exclude malignancy.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparoscopy / methods. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Rare Diseases. Risk Assessment. Splenectomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2002 Apr;52(4):307-12 [12031087.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Cancer. 1992 May 15;69(10):2449-53 [1568167.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1237-42 [17001153.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1963-6 [9772066.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):436-9 [15982220.001]
  • [Cites] Pancreas. 2006 Jul;33(1):96-9 [16804417.001]
  • [Cites] Pancreatology. 2006;6(3):248-53 [16543776.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1401-5 [8898845.001]
  • (PMID = 17338818.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1821026
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


9. Gómez-Pérez FJ, Cuevas-Ramos D, Valdés PA, Aguilar-Salinas CA, Mehta R, Rull JA: Beta-cell adenomas without hyperinsulinemia with use of highly specific insulin radioimmunoassays: case report and review of literature. Endocr Pract; 2010 Jul-Aug;16(4):660-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a case of a proinsulin-secreting islet cell adenoma in which the diagnosis was obscured by an ultraspecific insulin assay.
  • Magnetic resonance imaging and endoscopic ultrasonography confirmed the presence of a 2.5-cm tumor in the head of the pancreas.
  • CONCLUSION: The diagnosis of a hypoglycemia-producing pancreatic adenoma can be missed when an ultraspecific insulin assay is used.
  • The direct measurement of proinsulin established the diagnosis in this case.
  • [MeSH-major] Insulinoma / blood. Insulinoma / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis. Proinsulin / blood
  • [MeSH-minor] Diagnosis, Differential. Endosonography. Female. Humans. Hypoglycemia / blood. Insulin / blood. Magnetic Resonance Imaging. Middle Aged. Radioimmunoassay

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439243.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 9035-68-1 / Proinsulin
  •  go-up   go-down


10. Stamatakos M, Safioleas C, Tsaknaki S, Safioleas P, Iannescu R, Safioleas M: Insulinoma: a rare neuroendocrine pancreatic tumor. Chirurgia (Bucur); 2009 Nov-Dec;104(6):669-73
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulinoma: a rare neuroendocrine pancreatic tumor.
  • Insulinomas are functional endocrine tumors originating from the pancreatic b-cells.
  • In 1902 Nicholls described the first adenoma of pancreatic islets, while the first insulinoma was described in 1927 in Mayo Clinic, which was dissected two years later in 1929 in Toronto.
  • [MeSH-major] Insulinoma / diagnosis. Neuroendocrine Tumors / diagnosis. Pancreatic Neoplasms / diagnosis. Rare Diseases
  • [MeSH-minor] Diagnosis, Differential. History, 20th Century. Humans. Hypoglycemia / etiology. Pancreatectomy. Prevalence. Romania / epidemiology. Treatment Outcome


11. Hayasaka K, Nihashi T, Matsuura T, Itoh K, Tokuda H: Usefulness of F-18 FDG-PET in detection of multiple endocrine tumors with duodenal carcinoid. Comput Med Imaging Graph; 2007 Apr;31(3):191-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 76-year-old woman in whom hypercalcemia had been followed, whole body fluorodeoxyglucose positron emission tomography (FDG-PET) scan detected hypermetabolic areas in the left lower region of the thyroid gland, pancreas tail, and duodenum.
  • CT, MR, biopsy, and surgery were performed and parathyroid adenoma, pancreatic gastrinoma, and duodenal carcinoid were diagnosed.
  • Fluorine-18 (F-18) FDG-PET may be useful for diagnosis of multiple endocrine tumors with duodenal carcinoid.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Endocrine System / radiography. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383156.001).
  • [ISSN] 0895-6111
  • [Journal-full-title] Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  • [ISO-abbreviation] Comput Med Imaging Graph
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Machado MC, Machado MA: Solid serous adenoma of the pancreas: an uncommon but important entity. Eur J Surg Oncol; 2008 Jul;34(7):730-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid serous adenoma of the pancreas: an uncommon but important entity.
  • Serous cystic neoplasms of the pancreas have currently five recognized subtypes: serous microcystic adenoma, serous oligocystic ill-demarcated adenoma, solid serous adenoma, von Hippel-Lindau-associated cystic neoplasm, and serous cystadenocarcinoma.
  • Solid serous adenoma of the pancreas is by far the rarest subtype with only nine cases published thus far.
  • In this review, we will discuss clinical features, imaging characteristics and histopathological findings, considering in particular (1) difficulties in preoperative diagnosis; and (2) relevant immunohistochemical analysis.
  • After analyzing the literature, including one case from our Department, we can conclude that there is enough evidence to support that solid serous adenomas of the pancreas is a solid variant of serous cystadenomas.
  • Preoperative diagnosis is difficult to establish but magnetic resonance cholangiopancreatography may be useful.
  • Given benign nature of this solid variant conservative surgery is recommended.
  • It is definitively a rare entity but oncologic surgeons should be aware of this neoplasm in order to make a correct preoperative diagnosis that will ultimately result in more conservative surgeries.
  • [MeSH-major] Cystadenoma, Serous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440191.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 12
  •  go-up   go-down


13. Kitagawa H, Okabayashi T, Nishimori I, Kobayashi M, Sugimoto T, Akimori T, Kohsaki T, Miyaji E, Onishi S, Araki K: Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy. Int J Gastrointest Cancer; 2006;37(1):45-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy.
  • Abdominal computed tomography and upper abdominal ultrasonography revealed a large cystic mass in the body of the pancreas.
  • Endoscopic retrograde pancreatography showed no connection between the main pancreatic duct and the cystic lesion.
  • Pathological examination of the tumor revealed mucin-producing columnar epithelial cells lining the cystic wall with ovarian-type stromal tissue and no findings indicative of malignancy, giving a diagnosis of mucinous cystic adenoma of the pancreas.
  • Postpartum rapid growth of a benign mucinous cystic neoplasm might be linked to the production of female sex hormones during lactation.
  • [MeSH-major] Adenoma / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290080.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Colović R, Grubor N, Micev M, Ranković V, Matić S, Latincić S: [Serous microcystic adenoma of the head of the pancreas causing an obstructive jaundice]. Vojnosanit Pregl; 2008 Nov;65(11):839-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serous microcystic adenoma of the head of the pancreas causing an obstructive jaundice].
  • BACKGROUND: Serous microcystic adenoma is a rare benign tumor of the exocrine pancreas originating from the ductal system and composed of a large number of small cysts covered by cuboid cells, filled with clear serous fluid and separated with fibrocolagenous stroma.
  • Most frequently it appears in women in 7th and 8th decades, in the distal pancreas.
  • In 2/3 of patients symptoms are uncharacteristic and in 1/3 they are absent When localised within the head of the pancreas it rarely causes an obstructive jaundice.
  • At surgery we revealed a rather large policystic mass of the head of the pancreas causing not only obstructive jaundice but also a venous stasis by compression and dislocation of the portomesenteric vein.
  • Histology confirmed serous microcystic adenoma of the pancreas.
  • CONCLUSION: Although very rare, serous microcystic adenoma might appear within the head of the pancreas and has to be taken into consideration in differential diagnosis of cystic lesions of the head of the pancreas.
  • [MeSH-major] Cystadenoma, Serous / complications. Jaundice, Obstructive / etiology. Pancreatic Neoplasms / complications
  • [MeSH-minor] Female. Humans. Middle Aged. Pancreas, Exocrine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069716.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


15. Nobili C, Franciosi C, Degrate L, Caprotti R, Romano F, Perego E, Trezzi R, Leone BE, Uggeri F: A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient. Tumori; 2006 Sep-Oct;92(5):455-8
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient.
  • We report a case of the contemporaneous presence of two histologically different pancreatic neoplasms, one renal cancer and one embryogenic duodenal anomaly in a single patient.
  • Computed tomography confirmed the renal lesion, but also a heterogeneous mass within the pancreatic head appeared without bile ducts dilatation.
  • Abdominal magnetic resonance revealed a multiloculated cystic component of the pancreatic mass.
  • A second CT scan confirmed the renal and biliary findings, but it revealed a modest enlargement of the pancreatic asymptomatic mass.
  • Histopathologic analysis of the surgical specimen revealed mild differentiated papillary renal carcinoma, intraductal papillary mucinous adenoma of the pancreatic head, foci of intraepithelial pancreatic neoplasm and pancreatic heterotopy of duodenal muscular and submucosal layers.
  • [MeSH-major] Carcinoma, Pancreatic Ductal. Carcinoma, Papillary. Choristoma. Cystadenocarcinoma, Mucinous. Duodenal Diseases. Kidney Neoplasms. Neoplasms, Multiple Primary. Pancreas. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / diagnosis. Humans. Magnetic Resonance Imaging. Male. Nephrectomy / methods. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168444.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Reese SA, Traverso LW, Jacobs TW, Longnecker DS: Solid serous adenoma of the pancreas: a rare variant within the family of pancreatic serous cystic neoplasms. Pancreas; 2006 Jul;33(1):96-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid serous adenoma of the pancreas: a rare variant within the family of pancreatic serous cystic neoplasms.
  • We report the third case of a solid serous adenoma of the pancreas, a rare variant of tumor within the family of pancreatic serous cystic neoplasms.
  • Computed tomography of the abdomen demonstrated a 3.5-cm hypervascular mass in the head of the pancreas.
  • The microscopic findings of a solid neoplasm of cuboidal cells rich in glycogen and the immunostaining listed associate this tumor with the previously 2 reported cases of solid serous adenoma.
  • All 3 reported cases thus far have proven to be benign lesions by pathological examination.
  • Because clinical follow-up is reported only in the present case, caution should be exercised in declaring the solid serous adenoma of the pancreas as a benign lesion.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804417.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Bhople KS, Joshi AR, Patil SP, Tembhare PR: Microcystic adenoma of pancreas: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):334-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adenoma of pancreas: a case report.
  • Microcystic adenomas of the pancreas are rare benign neoplasms that occur most frequently in elderly females.
  • In this case report, we present a cystic neoplasm of pancreas in a 65-year-old lady who clinically presented with discomfort in the abdomen and hyperglycaemia.
  • Histopathological examination of surgical specimen confirmed the diagnosis of "Microcystic Adenoma ofPancreas".
  • Despite of the rarity, microcystic adenoma should kept in the mind as the differential diagnosis of cystic lesions of pancreas.
  • [MeSH-major] Adenoma / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Pancreatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883062.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Nagaike K, Chijiiwa K, Hiyoshi M, Ohuchida J, Kataoka H: Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule. Int J Clin Oncol; 2007 Oct;12(5):388-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule.
  • Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized entity representing a spectrum of benign and malignant neoplasms of the pancreas.
  • Preoperative distinction between benign and malignant IPMNs remains difficult.
  • Reported predictive factors for malignancy are size of the main pancreatic duct, cystic neoplasm, and mural nodule.
  • We report herein the case of a 50-year-old woman in whom a large mural nodule (30 mm) in the dilated main pancreatic duct (16 mm in diameter) was detected by ultrasonography, computed tomography, and endoscopic retrograde cholangiopancreatography.
  • Because the large mural nodule and dilatation of the main pancreatic duct were also detected by endoscopic ultrasonography (EUS) and intraductal ultrasonography (IDUS), the main-duct IPMN was considered to have malignant potential.
  • The final diagnosis was intraductal papillary mucinous adenoma of the pancreas.
  • The size of the mural nodule and the final diagnosis in this case suggest that the introduction of a novel molecular-biological approach might be necessary for the precise preoperative diagnosis of main-duct IPMN and adequate surgical treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929124.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Zhou J, Dong M, Kong F, Li Y, Tian Y: Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases. J Surg Oncol; 2009 Sep 1;100(3):273-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases.
  • BACKGROUND: To discuss the advantage of central pancreatectomy in the patients with benign tumors of the neck and body of the pancreas.
  • The operation is carried out by exposition of the pancreatic neck and body involved by the lesion.
  • Pancreatic fistula occurred in three cases and was treated conservatively.
  • CONCLUSION: Central pancreatectomy is a safe technique for benign tumors of the pancreatic neck and body, especially when the enucleation is very difficult.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / surgery. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Insulinoma / surgery. Male. Middle Aged. Pancreatic Fistula / etiology. Pancreatic Fistula / therapy. Postoperative Complications. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267362.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Yan JQ, Peng CH, Yang WP, Ding JZ, Zhou GW, Ma D, Li HW: Surgical management of benign duodenal tumours. ANZ J Surg; 2010 Jul-Aug;80(7-8):526-30
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of benign duodenal tumours.
  • BACKGROUND: While benign duodenal tumours are rare compared with malignant tumours, they comprise a wide variety of pathologies.
  • Despite their diagnostic challenge, the optimal management of benign duodenal tumours remains undefined.
  • We aimed to review the diagnosis and surgical treatment of benign duodenal tumours.
  • METHODS: Records of all patients with post-operative pathological diagnosis of benign duodenal tumour were retrieved.
  • The post-operative pathology results indicated 5 cases of adenoma, 2 cases of tubular adenoma, 2 cases of villous adenoma, 2 cases of tubulovillous adenoma, 2 cases of hamartoma and 1 case each of hamartomatous polyp, Brunner's adenoma, adenomyoma, fibromatosis and ectopic pancreas.
  • CONCLUSION: The presentation of benign duodenal tumours is non-specific, with upper abdominal discomfort and upper gastrointestinal bleeding as common symptoms.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Anastomosis, Surgical / methods. Biopsy, Needle. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Colectomy / methods. Duodenoscopy / methods. Female. Follow-Up Studies. Hamartoma / diagnosis. Hamartoma / pathology. Hamartoma / surgery. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Tomography, X-Ray Computed / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2011 Apr;81(4):300-1 [21418483.001]
  • (PMID = 20795967.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


21. Sanada Y, Yoshida K: A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes. J Gastrointestin Liver Dis; 2008 Dec;17(4):457-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of benign intraductal papillary mucinous neoplasm of the pancreas containing two major subtypes.
  • Here we report a case of benign intraductal papillary-mucinous neoplasm (IPMN) of the pancreas containing two major subtypes.
  • Histopathologic examinations revealed that IPMN was composed of gastric-type adenoma and intestinal-type borderline lesion.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Mixed Tumor, Malignant / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastrointestin Liver Dis. 2009 Jun;18(2):251-2 [19565062.001]
  • (PMID = 19104710.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mucin-2
  •  go-up   go-down


22. Gomez-Godinez V, Wakida NM, Dvornikov AS, Yokomori K, Berns MW: Recruitment of DNA damage recognition and repair pathway proteins following near-IR femtosecond laser irradiation of cells. J Biomed Opt; 2007 Mar-Apr;12(2):020505
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 800-nm 200-fs laser is used to produce DNA damage in rat kangaroo (PtK1) and human cystic fibrosis pancreatic adenoma carcinoma (CFPAC-1) cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477704.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 69337; United States / NCRR NIH HHS / RR / RR 14892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 9007-49-2 / DNA
  •  go-up   go-down


23. Nakayama Y, Inoue H, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Iwanaga S, Tani H, Ryu S, Yasunami Y, Ikeda S: Intraductal tubular adenoma of the pancreas, pyloric gland type: a clinicopathologic and immunohistochemical study of 6 cases. Am J Surg Pathol; 2005 May;29(5):607-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma of the pancreas, pyloric gland type: a clinicopathologic and immunohistochemical study of 6 cases.
  • The intraductal tubular adenoma (ITA), pyloric gland type, of the pancreas is an uncommon benign tumor, akin to the pyloric gland type adenoma of the gallbladder.
  • We report 6 cases of ITA of the pancreas: 3 male and 3 female aged 50 to 79 years (mean, 63.5 years; median, 65 years); all were examined clinicopathologically.
  • Grossly, all tumors formed a localized polypoid mass protruding into the lumen of the dilated pancreatic duct.
  • Five of the six tumors were found within the main duct, and the other arose within the branch duct of the pancreas.
  • In 2 cases, the adjacent pancreas showed foci of intraductal papillary-mucinous adenoma.
  • [MeSH-major] Adenoma / pathology. Gastric Mucosa / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832084.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Mucins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 9001-10-9 / Pepsinogen A
  •  go-up   go-down


24. Köninger J, Friess H, Wagner M, Kadmon M, Büchler MW: [Technique of pancreas-preserving duodenectomy]. Chirurg; 2005 Mar;76(3):273-81
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Technique of pancreas-preserving duodenectomy].
  • Even in pancreatic surgery, as in other organs, there is a tendency towards subtle organ-preserving techniques.
  • Benign duodenal tumors which cannot be resected transduodenally or multiple dysplastic duodenal adenomas in patients with familial adenomatous polyposis (FAP) usually require partial pancreaticoduodenectomy.
  • However, pancreas-preserving duodenectomy may represent a viable alternative.
  • This technique allows for the resection of the entire duodenum without resection of the pancreatic head.
  • Beside the preservation of pancreatic parenchyma and the reduction of the number of anastomoses, this technique offers the advantage of uncomplicated endoscopic follow-up.
  • In this article we describe the surgical technique of pancreas-preserving duodenectomy and our experience with this intervention.
  • [MeSH-major] Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Duodenal Neoplasms / surgery. Duodenum / surgery. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1997 Dec;35(12):1071-80 [9487639.001]
  • [Cites] Dis Colon Rectum. 1990 Aug;33(8):639-42 [2165452.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Aug;27(2):319-25 [3036342.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):62-7 [8554153.001]
  • [Cites] Chirurg. 1990 Apr;61(4):333-5 [2347273.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1301-6 [2703115.001]
  • [Cites] Lancet. 1988 May 21;1(8595):1149-51 [2896968.001]
  • [Cites] Scand J Gastroenterol Suppl. 1998;225:85-91 [9515758.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):771-9 [9860476.001]
  • [Cites] Arch Surg. 1996 Mar;131(3):247-52 [8611088.001]
  • [Cites] Surgery. 1995 Mar;117(3):254-9 [7878529.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):727-31 [15143902.001]
  • [Cites] Chirurg. 1995 Apr;66(4):350-9 [7634946.001]
  • (PMID = 15668807.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Mlika M, Farah F, Jarboui S, Abdessalem M, Zaouche A, Jilani SB, Zermani R: A benign cystic mass of the pancreas mimicking a malignant lesion. Pathologica; 2009 Dec;101(6):261-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A benign cystic mass of the pancreas mimicking a malignant lesion.
  • Herein, we highlight the diagnostic challenges of cystic pancreatic tumours, and report a case of chronic pancreatitis caused by a cystic tumour, which consisted in a canal dilatation--and not a pseudocyst.
  • The case thus demonstrates a rare association between a cystic form of chronic pancreatitis and adrenal adenoma.
  • Imaging findings (ultrasound, CT-scan, MRI) showed a 3-cm cystic lesion of the tail of the pancreas associated with a 3-cm adrenal mass.
  • Pathological findings consisted in fibrotic chronic pancreatitis with canal dilatation and an adrenal adenoma.
  • Pancreatic cystic lesions are rare tumours.
  • Final diagnosis must be based on pathological features.
  • [MeSH-major] Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology
  • [MeSH-minor] Adenoma / complications. Adenoma / pathology. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387716.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Ohno E, Hirooka Y, Itoh A, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Goto H: Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg; 2009 Apr;249(4):628-34
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
  • BACKGROUND AND AIM: Intraductal papillary mucinous neoplasms (IPMNs)have a wide pathologic spectrum and it is difficult to differentiate malignant from benign tumors.
  • RESULTS: Forty-two, 26, 16, and 3 were pathologically diagnosed as adenoma,noninvasive carcinoma, invasive IPMNs, and coexistent invasive ductal cancer, respectively.
  • The diagnosis of IPMNs with types III or IV mural nodule as malignant resulted in a sensitivity of 60%, specificity of 92.9%, and accuracy of 75.9%.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / ultrasonography. Endosonography / methods. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / ultrasonography. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Fine-Needle. Cohort Studies. Confidence Intervals. Contrast Media. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Logistic Models. Male. Mucous Membrane / pathology. Mucous Membrane / ultrasonography. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Probability. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300203.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


27. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • AIMS: Intraductal tubular adenoma (ITA) is an uncommon intraluminal polypoid lesion that occurs in the main pancreatic duct and involves the main pancreatic duct in the region of head or body.
  • Pancreatic intraepithelial neoplasia (PanIN) 1A and B was present in smaller ducts of all cases.
  • ITA could represent a localized, polypoid form of gastric-type IPMN.It is a benign lesion with no evidence of invasion and no direct tumour-related deaths.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Petersen M, Evert M, Schneider-Stock R, Pross M, Rüschoff J, Roessner A, Lippert H, Meyer F: Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC). Pathol Res Pract; 2009;205(11):801-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC).
  • Cystic tumor lesions of the pancreas are relatively uncommon.
  • A promoting aspect is the extended indication profile in pancreatic surgery, in particular, because of lower perioperative morbidity and mortality.
  • One of these classified cystic neoplasms of the pancreas is serous oligocystic adenoma (SOIA), a rare and benign tumor lesion.
  • We report on a 41-year-old man with a cystic lesion within the pancreatic head.
  • Both tumor tissue specimens had been characterized for a high level of microsatellite instability (MSI) and loss of hMLH1, as well as for a corresponding germ line mutation in hMLH1 gene, leading to the diagnosis of hereditary non-polyposis associated colon cancer (HNPCC).
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cystadenoma / genetics. Pancreatic Neoplasms / genetics


29. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasia of the pancreas: pathology and biology.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • For this reason, pancreatic cysts with mucinous differentiation ought to be evaluated carefully, preferably by experts familiar with subtle evidences of malignancy in these tumors.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • SPT holds a distinctive place among pancreatic neoplasia because of its highly peculiar characteristics, undetermined cell lineage, occurrence almost exclusively in young females, association with beta-catenin pathway, and also by being a very low-grade curable malignancy.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


30. Limi L, Liew NC, Badrul RH, Faisal MJ, Daniel YP: Duodenal intussusception of Brunner's gland adenoma mimicking a pancreatic tumour. Med J Malaysia; 2010 Dec;65(4):311-2
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal intussusception of Brunner's gland adenoma mimicking a pancreatic tumour.
  • Brunner's gland adenoma is a rare benign tumour of the duodenum.
  • We report a 40-year old lady, presenting with upper gastrointestinal bleeding and was found to have prolapsed and intussuscepted Brunner's gland adenoma of the duodenum, which mimicked the appearance of a tumour in the head of pancreas.
  • [MeSH-major] Adenoma / diagnosis. Brunner Glands / pathology. Duodenal Neoplasms / diagnosis. Intussusception / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21901954.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


31. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol; 2005 Feb;29(2):188-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas.
  • KOC (K homology domain containing protein overexpressed in cancer) is a novel oncofetal RNA-binding protein highly expressed in pancreatic carcinomas.
  • The purposes of this study were 1) to assess KOC mRNA expression in pancreatic carcinoma, 2) to determine the pattern of KOC immunoexpression among benign, borderline, and malignant pancreatic epithelial lesions, and 3) to evaluate the utility of the KOC antibody in distinguishing between these entities. mRNA was isolated from fresh pancreatic tissues (19 carcinomas, 2 normal pancreas, 1 chronic pancreatitis) and amplified using standard RT-PCR techniques.
  • Fifteen of 19 (79%) carcinomas overexpressed KOC mRNA relative to non-neoplastic tissue samples and expression increased progressively with tumor stage: the mean copy number of KOC mRNA transcripts was 1.5, 11.1, 31, and 28 for stage I, II, III, and IV carcinomas, respectively, compared with 0.9 and 1 for normal pancreatic tissue and chronic pancreatitis, respectively.
  • Severe dysplasia of the ductal epithelium, present in 19 foci of intraductal papillary mucinous carcinoma, mucinous cystadenocarcinoma, and grade 3 pancreatic intraepithelial neoplasia (PanIN3) showed strong or moderate staining in 15 (79%) cases, whereas foci of mild and moderate dysplasia (intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms with adenoma and/or moderate dysplasia, PanIN1, and PanIN2) were uniformly negative for this marker in 25 and 22 cases, respectively.
  • In the normal pancreas, weak background staining of acini was present in 12 of 50 (24%) cases but was easily distinguishable from the type of staining identified in neoplastic epithelium, and benign ducts and ductules were negative in all cases.
  • We conclude that KOC is a sensitive and specific marker for carcinomas and high-grade dysplastic lesions of the pancreatic ductal epithelium.
  • Therefore, immunostains directed against KOC may be of diagnostic utility in the evaluation of pancreatic lesions, particularly when biopsy material is limited.
  • [MeSH-major] Biomarkers, Tumor / analysis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644775.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


32. Yamaguchi K, Nakamura M, Shirahane K, Kawamoto M, Konomi H, Ohta M, Tanaka M: Pancreatic juice cytology in IPMN of the pancreas. Pancreatology; 2005;5(4-5):416-21; discussion 421
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in IPMN of the pancreas.
  • BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is a disease ranging from adenoma to borderline (with moderate dysplasia) and further to carcinoma (noninvasive and invasive) and surgical strategy is different by the grades of dysplasia.
  • METHODS: Preoperative pancreatic juice cytology in IPMN was reviewed in 71 patients with IPMN who underwent surgical resection.
  • RESULTS: The IPMN was adenoma in 48 patients, borderline in 13 and carcinoma (invasive) in 10.
  • The sensitivity of pancreatic juice cytology in malignant IPMN was 40% (4/10).
  • In 4 patients with the 48 IPM adenomas, diagnosis of pancreatic juice cytology was class IV or V.
  • Sensitivity of pancreatic juice cytology was higher in IPMN of the main duct type with mucin hypersecretion and with mural nodules.
  • CONCLUSIONS: These findings suggest that pancreatic juice cytology in IPMN is useful especially in the main duct type with mucin hypersecretion and mural nodules.
  • When the diagnosis of pancreatic juice cytology is malignant in otherwise benign-looking IPMNs, coexistence of pancreatic carcinoma should be suspected.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Cytodiagnosis / methods. Pancreatic Juice / cytology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / classification. Adenoma / diagnosis. Aged. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985766.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Kitagawa T, Nagano H, Umeshita K, Wakasa K, Doki Y, Mori M: Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep; 2010 Sep;24(3):613-20
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
  • Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas presents in various histopathological stages from benign to malignant lesions.
  • The differentiation between benign and malignant IPMN is important in order to determine the treatment of the patients.
  • The aim of this study was to assess the utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in pre-operative differentiation of benign and malignant IPMN of the pancreas.
  • The maximum standardized uptake value (SUVmax) was determined on FDG-PET, and differentiation of benign from malignant IPMN was tested using various SUVmax cut-off levels and various parameters derived from the CT.
  • SUVmax was found to be significantly higher in malignant IPMNs (4.7+/-3.0) than that in benign IPMNs (1.8+/-0.3, P=0.0011).
  • SUVmax values correlated with the histopathological types of IPMN (adenoma/borderline lesion/carcinoma in situ/invasive carcinoma) (Spearman rank correlation 0.865, P<0.0001).
  • The combination of mural nodule, detected on CT, and SUVmax of 2.5 offered the best diagnosis of malignant IPMN.
  • These results suggest that FDG-PET is useful for differentiation of malignant IPMN of the pancreas, and that it should be performed in combination with other conventional imaging modalities.
  • [MeSH-major] Adenoma / radionuclide imaging. Carcinoma in Situ / radionuclide imaging. Carcinoma, Pancreatic Ductal / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasms, Cystic, Mucinous, and Serous / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Japan. Male. Middle Aged. Pancreatectomy. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664965.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Fitzhugh VA, Mirani N, Aisner S, Koneru B, Das K: Preoperative fine needle aspiration cytology diagnosis of microcystic adenoma of the pancreas: fact or fiction? A report of 2 cases. Acta Cytol; 2008 Mar-Apr;52(2):240-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative fine needle aspiration cytology diagnosis of microcystic adenoma of the pancreas: fact or fiction? A report of 2 cases.
  • BACKGROUND: Microcystic adenoma is an uncommon benign neoplasm involving the pancreas that usually affects older populations.
  • CASES: We report 2 cases of microcystic adenoma of the pancreas in which an accurate diagnosis could not be rendered on cytology material alone.
  • CONCLUSION: A preoperative diagnosis can be helpful in guiding the care of the patient, thereby increasing the importance of a diagnosis to distinguish between a benign vs. malignant process.
  • These case reports demonstrate the difficulty of obtaining diagnostic cells in microcystic adenoma, highlight the use of FNA to increase cellular yield and emphasize the importance of correlating radiologic findings with aspiration of abundant watery fluid from cystic pancreatic masses to make a definitive diagnosis.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500004.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kawamoto S, Horton KM, Lawler LP, Hruban RH, Fishman EK: Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT? Radiographics; 2005 Nov-Dec;25(6):1451-68; discussion 1468-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT?
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct clinicopathologic entity that is being recognized with increasing frequency.
  • The spectrum of appearances of IPMN, which includes adenoma, borderline lesion, and lesions with associated carcinoma in situ or invasive carcinoma, was studied with 16-section multidetector computed tomography (CT) and histologic correlation.
  • Features predictive of invasive carcinoma in IPMN at CT and other imaging studies include involvement of the main pancreatic duct, marked dilatation of the main pancreatic duct, diffuse or multifocal involvement, the presence of a large mural nodule or solid mass, large size of the mass, and obstruction of the common bile duct.
  • [MeSH-major] Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Papillary / radiography. Neoplasms, Multiple Primary / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16284127.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


36. Konishi M, Kinoshita T, Nakagohri T, Takahashi S, Gotohda N, Ryu M: Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies. Hepatogastroenterology; 2007 Apr-May;54(75):753-7
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies.
  • BACKGROUND/AIMS: Pancreas-sparing duodenectomy (PSD) represents an attractive operation for benign or premalignant duodenal disease.
  • METHODOLOGY: The present study investigated 16 patients who underwent PSD for duodenal neoplasms including adenoma, cancer, carcinoid and non-epithelial tumor.
  • This study classified PSD into 4 types based on the resected portion of the duodenum, as used in gastrectomy (total, subtotal, distal, and proximal) and we experienced pancreas-sparing proximal duodenectomy and pancreas-sparing distal duodenectomy.
  • RESULTS: Pancreatic fistula or anastomotic leak occurred in 2 patients, and were closed with nonoperative management.
  • The remaining 10 patients are well, with no symptoms related to the hepatobiliary and pancreatic systems.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


37. Gourgiotis S, Ridolfini MP, Germanos S: Intraductal papillary mucinous neoplasms of the pancreas. Eur J Surg Oncol; 2007 Aug;33(6):678-84
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas.
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms (IPMNs) are neoplasms of the pancreatic duct epithelium characterized by intraductal papillary growth and thick mucin secretion.
  • Quantities of mucin fill the main and/or branches of pancreatic ducts and cause ductal dilatation.
  • This review encompasses IPMNs, including symptoms, diagnosis, management, and prognosis.
  • Most branch type IPMNs are benign, while the other two types are frequently malignant.
  • Presence of a large branch type IPMN and marked dilatation of the main duct indicate the existence of adenoma at least.
  • CONCLUSIONS: Prognosis is excellent after complete resection of benign and non-invasive malignant IPMNs.
  • The extent of pancreatic resection and the intraoperative management of resection margins remain controversial.
  • Total pancreatectomy should be reserved for patients with resectable but extensive IPMNs involving the whole pancreas; its benefits, however, must be balanced against operative and postoperative risks.
  • [MeSH-major] Pancreatic Ducts / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Dilatation, Pathologic / pathology. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207960.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


38. Adsay NV, Basturk O, Cheng JD, Andea AA: Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol; 2005 Oct;15(4):254-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
  • Most pancreatic neoplasia are of ductal lineage, characterized by tubule (gland), cyst, papilla, or mucin formation and expression of mucin-related glycoproteins and oncoproteins (eg, MUC1, CA19-9, CEA, DUPAN), as well as some subsets of cytokeratin (eg, CK19).
  • A variety of pancreatic neoplasia fall under the heading of ductal neoplasia.
  • Invasive ductal adenocarcinoma (DA) is the most important and constitutes the vast majority (>85%) of pancreatic tumors.
  • The presumed precursors of DA are microscopic intraductal proliferative changes that are now termed pancreatic intraepithelial neoplasia (PanIN).
  • Colloid carcinoma of the pancreas appears to be a clinicopathologically distinct tumor with indolent behavior.
  • Whereas most ductal pancreatic neoplasia are characterized by some degree of mucin formation, serous tumors, of which serous (microcystic) adenoma is the sole example, lack mucin formation, presumably because they recapitulate centroacinar ducts.
  • They are typically benign tumors.
  • It is recognized now that pancreatic carcinoma, like other malignant processes, is a genetic disease produced by progressive mutations in cancer-related genes.
  • Ductal neoplasia is the most important category among pancreatic tumors.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology


39. Pauser U, Kosmahl M, Sipos B, Klöppel G: [Mesenchymal tumors of the pancreas. Surprising, but not uncommon]. Pathologe; 2005 Feb;26(1):52-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesenchymal tumors of the pancreas. Surprising, but not uncommon].
  • Mesenchymal tumors of the pancreas are rare.
  • They are resected because a solid or cystic pancreatic tumor is suspected.
  • Benign mesenchymal tumors comprise lymphangiomas, hemangiomas, schwannomas, solitary fibrous tumors, adenomatoid tumors, clear cell tumors, and hamartomas.
  • It is important to differentiate these tumors from anaplastic carcinomas and retroperitoneal tumors that infiltrate pancreatic tissue.
  • [MeSH-major] Mesoderm / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Hemangioma / pathology. Humans. Incidence. Lymphangioma / pathology. Neurilemmoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592845.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Fujii T, Kato K, Kodera Y, Kanda M, Nagai S, Yamada S, Kanzaki A, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakamura S, Nakao A: Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery; 2010 Aug;148(2):285-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas often recurs after operative resection.
  • The absolute risk and incidence of recurrence, however, especially in the remnant pancreas, is unknown.
  • METHODS: We reviewed our 18-year experience of 144 surgical cases of IPMNs and selected 103 cases of benign IPMN and carcinoma in situ (CIS) for analysis of the clinicopathologic features and long-term outcome of the recurrent disease, with particular emphasis on the status of the cut margins of the pancreas.
  • RESULTS: No patient with benign IPMN died within 5 years.
  • Recurrences in the remnant pancreas were observed in 9 cases: 4 (4.9%) among the 81 cases of benign IPMNs and 5 (22.7%) among the 22 cases of CIS.
  • The pancreatic transection margin was normal or hyperplastic in 64 patients, whereas adenoma was detected at the margin in 28 patients.
  • The presence of adenoma had no influence on the outcome, and recurrence in the remnant pancreas was diagnosed in 5 (7.8%) of 64 adenoma-negative patients and 3 (10.7%) of 28 adenoma-positive patients.
  • CONCLUSION: In benign IPMN and CIS, a favorable prognosis can be expected irrespective of the status of the pancreatic cut surface, although follow-up with adequate imaging studies is recommended for detection and resection of the recurrent disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pancreas / pathology. Prognosis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20434746.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Solís-López DR, Rodríguez-Hernández Z, Solís-López DH: Incidental adreno-cortical adenoma, why surgery? a case report. P R Health Sci J; 2010 Jun;29(2):130-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental adreno-cortical adenoma, why surgery? a case report.
  • INTRODUCTION: Incidental adrenal tumors are commonly benign, but reports demonstrate that if the characteristics of the tumor are not clear, on images surgery is the procedure of choice.
  • The pathological report was adrenal cortical adenoma with central hemorrhage and not a myelolipoma as described in images on magnetic resonance imaging (MRI).
  • CONCLUSION: The use of imaging for diagnosis, clinical management and decision making is very controversial.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Adenoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496530.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


42. Aparajita R, Gomez D, Verbeke CS, Menon KV: Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum. JOP; 2008;9(2):212-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum.
  • CONTEXT: Benign tumours of the biliary tract are an extremely rare group of neoplasms.
  • The diagnosis of these rare tumours is established on histopathological analysis following resection.
  • Coincidence of a biliary adenoma of the distal common bile duct and a synchronous adenocarcinoma of the peri-ampullary duodenum has never been reported in the literature.
  • CASE REPORT: We report a case of a papillary adenoma in the common bile duct in a 75-year-old female, who had synchronous invasive adenocarcinoma of the peri-ampullary duodenum.
  • CONCLUSION: Isolated papillary adenoma of the bile duct is extremely rare, and in this unusual case it coincided with a peri-ampullary duodenal adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326932.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Spalding DR, Isla AM, Thompson JN, Williamson RC: Pancreas-sparing distal duodenectomy for infrapapillary neoplasms. Ann R Coll Surg Engl; 2007 Mar;89(2):130-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreas-sparing distal duodenectomy for infrapapillary neoplasms.
  • INTRODUCTION: For neoplasms that arise in the third and fourth parts of the duodenum (D(3), D(4)), a duodenectomy that preserves the pancreas can provide adequate tumour clearance while avoiding the additional dissection and risk of the common alternative, pancreatoduodenectomy.
  • PATIENTS AND METHODS: Pancreas-sparing distal duodenectomy (PSDD) was performed in 14 patients with infrapapillary duodenal neoplasms between 1991-2002, and the clinical outcome is reviewed.
  • The operation entails careful separation of the lower pancreatic head from D(3), complete mobilisation of the ligament of Treitz and end-to-end duodenojejunal anastomosis 1-3 cm below the major duodenal papilla.
  • There were 11 malignant neoplasms (adenocarcinoma 5, stromal tumour 4, recurrent seminoma 1, plasmacytoma 1), 2 benign neoplasms (villous adenoma, lipoma) and 1 patient with steroid-induced ulceration.
  • Median operation time was 240 min and median blood loss 1197 ml, being greater for malignant than benign lesions (1500 ml versus 700 ml).
  • There was one death from gangrenous cholecystitis, one early re-operation for anastomotic bleeding and one late re-operation for delayed gastric emptying secondary to anastomotic stricture, but no pancreatic complications.
  • Although a major undertaking in its own right, it avoids the extra time of a pancreatic resection and the extra risk of a pancreatic anastomosis.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Duodenal Neoplasms / surgery. Pancreas / surgery. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1533-6 [10613470.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1953-8 [10430376.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(4):414-7 [10664293.001]
  • [Cites] Dig Surg. 2000;17(4):410-2 [11053954.001]
  • [Cites] Ned Tijdschr Geneeskd. 2002 Mar 30;146(13):621-4 [11957383.001]
  • [Cites] Arch Surg. 2002 May;137(5):557-62; discussion 562-3 [11982469.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Eur J Surg. 2002;168(2):74-7 [12113274.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1362-3 [12072993.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):393-6 [12353155.001]
  • [Cites] Hepatogastroenterology. 2003 May-Jun;50(51):711-3 [12828067.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):727-31 [15143902.001]
  • [Cites] Surg Gynecol Obstet. 1976 Jun;142(6):858-60 [936029.001]
  • [Cites] Am J Proctol Gastroenterol Colon Rectal Surg. 1981 Aug;32(8):18-21, 28 [7027808.001]
  • [Cites] Ann Surg. 1983 Feb;197(2):172-8 [6337568.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2242-50 [4052969.001]
  • [Cites] World J Surg. 1985 Dec;9(6):914-20 [4082613.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):184-6 [3349313.001]
  • [Cites] Ann Surg. 1989 May;209(5):593-8; discussion 598-9 [2650645.001]
  • [Cites] Ann Surg. 1989 Oct;210(4):544-54; discussion 554-6 [2679459.001]
  • [Cites] Arch Surg. 1990 Aug;125(8):961-5 [2378560.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):945-9; discussion 949-50 [1353671.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] J Surg Oncol. 1995 Jan;58(1):70-3 [7823577.001]
  • [Cites] Surgery. 1995 Mar;117(3):254-9 [7878529.001]
  • [Cites] Ann R Coll Surg Engl. 1994 Nov;76(6):403-4 [7702324.001]
  • [Cites] Jpn J Clin Oncol. 1995 Jun;25(3):109-12 [7596048.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):62-7 [8554153.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):835-8 [8884299.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):983-94 [9287993.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):79-87 [9841972.001]
  • [Cites] Dig Surg. 1998;15(5):398-403 [9845621.001]
  • [Cites] Dig Surg. 1999;16(1):22-5 [9949263.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):13-21, discussion 22-3 [10631358.001]
  • (PMID = 17346405.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1964558
  •  go-up   go-down


44. A-Cienfuegos J, Rotellar F, Martí-Cruchaga P, Valentí V, Zozaya G, Bueno A, Pedano N, Lozano MD, Sola JJ, Pardo F: Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results. Rev Esp Enferm Dig; 2010 May;102(5):314-20
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results.
  • BACKGROUND: intraductal papillary mucinous neoplasm (IPMN) shows a series of lesions which evolve from benign lesions -adenoma- to invasive carcinoma.
  • In five cases, the IPMN was combined type (both main and branch pancreatic ducts involved) in four main duct-type and branch duct-type in the another six as well.
  • A patient without invasive carcinoma died at 66 months of follow-up for pancreas adenocarcinoma.
  • [MeSH-major] Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Papilloma, Intraductal / pathology. Papilloma, Intraductal / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Pancreas / pathology. Pancreas / surgery. Pancreaticoduodenectomy. Postoperative Period. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524759.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


45. Ishida M, Egawa S, Aoki T, Sakata N, Mikami Y, Motoi F, Abe T, Fukuyama S, Sunamura M, Unno M, Moriya T, Horii A, Furukawa T: Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas; 2007 Nov;35(4):348-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
  • OBJECTIVES: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas encompasses a spectrum of neoplasms with both morphological and immunohistochemical variations of mucin glycoproteins.
  • Characteristically, the gastric-type IPMNs were likely to be diagnosed as benign, to be confined to branch ducts, and to have fair prognoses.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090241.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


46. Yamaguchi H, Ishigami K, Inoue T, Eguchi T, Nagata S, Kuroda Y, Nishihara Y, Yamaguchi K, Tanaka M, Tsuneyoshi M: Three cases of serous oligocystic adenomas of the pancreas; evaluation of cyst wall thickness for preoperative differentiation from mucinous cystic neoplasms. J Gastrointest Cancer; 2007;38(1):52-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of serous oligocystic adenomas of the pancreas; evaluation of cyst wall thickness for preoperative differentiation from mucinous cystic neoplasms.
  • BACKGROUND: Serous oligocystic adenoma (SOA), a rare pancreatic neoplasm, is generally a benign lesion without the necessity of surgery.
  • The purpose of this study was to evaluate the cyst wall thickness of SOAs and MCNs for preoperative differential diagnosis.
  • The cyst wall thickness of the SOAs was evaluated in the area protruding out of the pancreas and was compared with that of 13 MCNs histopathologically.
  • [MeSH-major] Adenoma / pathology. Cysts / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Preoperative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065725.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tanaka M, Kobayashi K, Mizumoto K, Yamaguchi K: Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2005 Jul;40(7):669-75
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) is a spectrum of neoplasia in the pancreatic duct epithelium characterized by cystic dilation of the main and/or branch pancreatic duct.
  • Most branch duct IPMNs are benign, whereas the other two types are often malignant.
  • A large size of branch duct IPMN and marked dilation of the main pancreatic duct indicate the presence of adenoma at least.
  • Of recent interest is the relatively high prevalence of synchronous and/or metachronous malignancy in various organs, including the pancreas.
  • The prognosis is favorable after complete resection of benign and noninvasive malignant IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatectomy / methods. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082582.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 58
  •  go-up   go-down


48. Liang H, Wang XN, Wang BG, Pan Y, Ding XW, Hao XS: [Management of nonfunctioning islet cell tumors of the pancreas]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):457-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of nonfunctioning islet cell tumors of the pancreas].
  • OBJECTIVE: To analyze the clinical and pathological features in order to investigate appropriate way of diagnosis and treatment for non-functional islet cell tumors of the pancreas (NFICT).
  • Twenty-eight patients were diagnosed as having non-functional islet cell carcinomas of the pancreas (NFICC) and 15 patients benign islet cell tumors.
  • Preoperatively, all of those were found to have a mass in their pancrease by ultrasonic and computed tomography examination, with 21 in the head, 10 in the body and 6 in the tail of the pancreas.
  • The resectability and curative resection rate in 28 patients with nonfunctioning islet cell carcinomas of the pancreas was 78.6% and 60.7%, respectively.
  • None of the 15 patients with benign nonfunctioning islet cell tumor of the pancreas died of this disease.
  • While the overall cumulative 5- and 10-year survival rate in 28 patients with non-functional islet cell carcinomas of the pancreas was only 58.1% and 29.0%, respectively.
  • CONCLUSION: Nonfunctioning islet cell tumor of the pancreas is frequently found in young female.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974283.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


49. Yüksel M, Eziddin S, Wardelmann E, Biersack HJ: 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Rev Esp Med Nucl; 2006 Sep;25(5):316-9
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy.
  • A patient with suspicion of a neuroendocrine tumor of the pancreas underwent a somatostatin receptor scintigraphy using 111In-Pentetreotide.
  • 111In-pentetreotide scintigraphy showed discrete uptake of the radiotracer in the head of the pancreas and focal uptake in the right upper thyroid lobe.
  • Adding a 48h planar image might contribute to the differential diagnosis between benign or malignant lesions, as in the present case where the uptake decreased in an adenoma after 48 hours.
  • [MeSH-major] Adenoma / radionuclide imaging. Indium Radioisotopes / pharmacokinetics. Neuroendocrine Tumors / radionuclide imaging. Neuroendocrine Tumors / secondary. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics. Somatostatin / analogs & derivatives. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Chromogranin A / analysis. Diagnosis, Differential. False Positive Reactions. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / radionuclide imaging. Receptors, Somatostatin / metabolism. Serotonin / analysis. Thyroglobulin / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173778.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Indium Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 333DO1RDJY / Serotonin; 51110-01-1 / Somatostatin; 9010-34-8 / Thyroglobulin; G083B71P98 / pentetreotide
  •  go-up   go-down


50. Schulz HU, Kellner U, Kahl S, Effenberger O, Asperger W, Lippert H, Röcken C: A giant pancreatic serous microcystic adenoma with 20 years follow-up. Langenbecks Arch Surg; 2007 Mar;392(2):209-13
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for microcystic adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A giant pancreatic serous microcystic adenoma with 20 years follow-up.
  • BACKGROUND AND AIMS: There is only little information about the spontaneous course of large pancreatic serous tumours.
  • We followed up a white woman with a giant serous microcystic adenoma over more than 20 years.
  • Finally, the initial biopsy specimen was re-evaluated, using immunohistochemistry, and the final diagnosis of a serous microcystic adenoma was made.
  • CONCLUSION: This unique case demonstrates that the spontaneous course of serous microcystic adenoma of the pancreas may be favourable even with huge tumour size and that immunohistochemistry may prove a valuable tool for differential diagnosis of cystic pancreatic lesions.
  • Due to their size and progressive, space-occupying growth, these biologically benign tumours may cause injury to adjacent organs and thus clinical symptoms.

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235583.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


51. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • METHODS: Thirty-seven patients with IPMN of the pancreas, confirmed by surgical resection and typical findings of endoscopic ultrasonography and CT imaging between October 1, 1998 and August 31, 2006 were included.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


52. Sugiyama M, Suzuki Y, Abe N, Mori T, Atomi Y: Management of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol; 2008;43(3):181-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraductal papillary mucinous neoplasm of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a distinct entity characterized by papillary proliferations of mucin-producing epithelial cells with excessive mucus production and cystic dilatation of the pancreatic ducts.
  • IPMNs have malignant potential and exhibit a broad histologic spectrum, ranging from adenoma to invasive carcinoma.
  • The postoperative 5-year survival rate is nearly 100% for benign tumors and noninvasive carcinoma, and approximately 60% for invasive carcinoma.
  • Surgical treatment is indicated for a branch duct IPMN with suspected malignancy (tumor diameter > or = 30 mm, mural nodules, dilated main pancreatic duct, or positive cytology) or positive symptoms.
  • IPMNs are associated with a high incidence of extrapancreatic malignancies and pancreatic ductal carcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373159.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 37
  •  go-up   go-down


53. Kuroki T, Tajima Y, Tsutsumi R, Tsuneoka N, Kitasato A, Adachi T, Kanematsu T: Endoscopic naso-pancreatic stent-guided single-branch resection of the pancreas for multiple intraductal papillary mucinous adenomas. World J Gastroenterol; 2006 Nov 28;12(44):7203-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic naso-pancreatic stent-guided single-branch resection of the pancreas for multiple intraductal papillary mucinous adenomas.
  • In benign or low-grade malignant pancreatic tumors, complete removal of the lesion is sufficient for a cure, and thus minimal resection techniques with preservation of the pancreatic functional reserve have advantages over more extended pancreatic resections.
  • However, a high incidence of postoperative pancreatic fistula in such procedures has been reported.
  • Moreover, branch-type intraductal papillary mucinous neoplasms of the pancreas tend to locate in the head of the pancreas, and show less malignant potential.
  • We describe an endoscopic naso-pancreatic stent-guided single-branch resection of the pancreas for branch-type multiple intraductal papillary mucinous adenomas, along with a gastric wall-covering method for the prevention of pancreatic leakage.
  • [MeSH-major] Adenoma / surgery. Endoscopy, Digestive System / methods. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):156-62 [14505149.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):220-4 [15036200.001]
  • [Cites] Am J Surg. 2006 Jun;191(6):823-6 [16720158.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(1):71-5 [15754104.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(4):283-5 [16133693.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • (PMID = 17131488.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087787
  •  go-up   go-down


54. Yamaguchi T, Baba T, Ishihara T, Kobayashi A, Nakamura K, Tadenuma H, Ito H, Miyazaki M, Saisho H: Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol; 2005 Nov;3(11):1136-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography.
  • BACKGROUND & AIMS: Most intraductal papillary mucinous neoplasms of the pancreas (IPMNs) have a favorable prognosis.
  • METHODS: Eighty-one patients with IPMN were periodically subjected to US (>3 years); 27 were reviewed retrospectively (12 with benign neoplasms [adenoma, borderline] and 15 with malignant tumors [carcinoma in situ, invasive cancer]) and 54 prospectively.
  • US examination was focused on the main pancreatic duct (MPD) diameter, cyst diameter, and presence or absence and height of the protruding lesion.
  • Differences between the benign and malignant groups were examined to set the criteria for surgical treatment.
  • The majority of the prospective patients showed no significant changes of these parameters; however, 2 patients (3.7%) were operated on, with the post-surgery histopathologic diagnosis of cancer.
  • [MeSH-major] Carcinoma, Papillary / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Pancreatic Ductal / ultrasonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pancreatic Ducts / ultrasonography. Prospective Studies. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271346.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Sidden CR, Mortele KJ: Cystic tumors of the pancreas: ultrasound, computed tomography, and magnetic resonance imaging features. Semin Ultrasound CT MR; 2007 Oct;28(5):339-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic tumors of the pancreas: ultrasound, computed tomography, and magnetic resonance imaging features.
  • Cystic tumors of the pancreas are a subset of rare pancreatic tumors that vary from benign to malignant.
  • This article aims to review the histopathologic and imaging findings of the relatively common lesions (serous microcystic adenoma, mucinous cystic tumor, intraductal papillary mucinous tumor, and solid pseudopapillary tumor) and uncommon lesions (cystic endocrine tumors, cystic metastases, cystic teratomas, and lymphangiomas) in this group.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Contrast Media. Cystadenocarcinoma / diagnosis. Cystadenocarcinoma / pathology. Cystadenoma / diagnosis. Cystadenoma / pathology. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970551.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 43
  •  go-up   go-down


56. Miura T, Igarashi Y, Okano N, Miki K, Okubo Y: Endoscopic diagnosis of intraductal papillary-mucinous neoplasm of the pancreas by means of peroral pancreatoscopy using a small-diameter videoscope and narrow-band imaging. Dig Endosc; 2010 Apr;22(2):119-23
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic diagnosis of intraductal papillary-mucinous neoplasm of the pancreas by means of peroral pancreatoscopy using a small-diameter videoscope and narrow-band imaging.
  • Therefore, it is important to determine whether an IPMN is benign or malignant.
  • We carried out the differential diagnosis of benign lesion to malignant lesion.
  • METHODS: Between April 2003 and May 2009, PPS using a small-diameter videoscope by means of NBI was carried out on 21 hospitalized patients with IPMN (10 cases of adenocarcinoma, 11 cases of adenoma or hyperplasia; 14 males and seven females, with a mean age of 69.4 years).
  • RESULTS: Fifteen focal lesions of the 16 cases in the head of the pancreas (93.7%) and four focal lesions of the five cases in the pancreatic body (80%) were observable, whereas two lesions (adenocarcinoma in the pancreatic body, and adenoma in the uncus of pancreas) were not observable.
  • Ten cases with sessile type or semipedunculated type were diagnosed as adenoma or hyperplasia.
  • CONCLUSIONS: When combined with a videoscope and NBI, pancreatoscopy provided a clear image and was useful for evaluating whether the IPMN was benign or malignant.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Endoscopes. Endoscopy, Digestive System / instrumentation. Pancreatic Ducts. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Equipment Design. Female. Humans. Hyperplasia / diagnosis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447205.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


57. Hayashibe A, Sakamoto K, Shinbo M, Makimoto S, Nakamoto T: A resected case of multiple intraductal papillary mucinous tumors of the pancreas with US-guided ductal branch-oriented partial pancreatectomy. Pancreatology; 2005;5(4-5):462-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A resected case of multiple intraductal papillary mucinous tumors of the pancreas with US-guided ductal branch-oriented partial pancreatectomy.
  • The cystic tumor of pancreas head had a diameter of 2 cm, and the mural nodule of the cystic tumor measured only 3 mm.
  • In the pancreas body the cystic tumor was measured at 1.5 cm with the mural nodule of the cystic tumor measuring 3 mm.
  • It was believed that the tumors were benign.
  • The reduction operation for preservation of pancreatic parenchyma should be selected for these circumstances.
  • Ductal branch-oriented partial pancreatectomy was performed on September 6, 2002 with intraoperative ultrasonography and a Cavitron Ultrasonic Aspirator, preserving the main pancreatic duct and normal pancreatic parenchyma.
  • The operation was successful, and the histopathological diagnosis of the tumors was intraductal papillary adenoma of the pancreas.
  • [MeSH-major] Adenoma / surgery. Digestive System Surgical Procedures. Pancreatectomy / methods. Pancreatic Ducts / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985773.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


58. Ishikawa T, Itoh A, Kawashima H, Ohno E, Matsubara H, Itoh Y, Nakamura Y, Nakamura M, Miyahara R, Hayashi K, Ishigami M, Katano Y, Ohmiya N, Goto H, Hirooka Y: Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc; 2010 May;71(6):951-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors.
  • BACKGROUND: Pancreatic endocrine tumors (PETs) develop in relatively few patients, but they are often difficult to diagnose because of their small size and various clinical symptoms.
  • OBJECTIVE: The aim of this study was to investigate the usefulness of EUS combined with contrast enhancement (CE-EUS) in the preoperative localization of PETs and the differentiation between malignant and benign PETs.
  • [MeSH-major] Pancreas / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / ultrasonography. Adult. Aged. Carcinoma, Islet Cell / pathology. Carcinoma, Islet Cell / ultrasonography. Contrast Media. Diagnosis, Differential. Endosonography. Female. Humans. Male. Middle Aged. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20438884.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


59. Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab; 2005 Jun;19(2):195-211
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and localization of islet-cell tumours of the pancreas on CT and MRI.
  • Islet-cell tumours are neuroendocrine tumours that arise from the endocrine pancreas.
  • They range from benign to malignant.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Gastrinoma / diagnosis. Humans. Insulinoma / diagnosis. Islets of Langerhans / pathology. Multiple Endocrine Neoplasia Type 1 / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763695.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


60. Manfredi R, Graziani R, Motton M, Mantovani W, Baltieri S, Tognolini A, Crippa S, Capelli P, Salvia R, Pozzi Mucelli R: Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis. Radiology; 2009 Oct;253(1):106-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis.
  • PURPOSE: To retrospectively determine the accuracy of magnetic resonance (MR) imaging combined with MR cholangiopancreatography (CP) in differentiating benign from malignant intraductal papillary mucinous neoplasms (IPMNs) involving the main pancreatic duct (MPD), with histopathologic analysis as the reference standard.
  • Qualitative image analysis included assessment of the site of MPD dilatation (head of the pancreas, body and/or tail of the pancreas, or diffuse), presence or absence of duct wall nodules, and contrast enhancement of the MPD walls.
  • MPD wall nodules were observed in 16 carcinomas involving the MPD and one adenoma or borderline neoplasm (P < .00001).
  • The median maximal diameter of the MPD was 18 mm in malignant MPD or mixed type IPMNs and 11 mm in benign borderline IPMNs (P = .038).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Cholangiopancreatography, Magnetic Resonance. Magnetic Resonance Imaging / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Diagnosis, Differential. Female. Ferrosoferric Oxide. Humans. Image Interpretation, Computer-Assisted. Logistic Models. Magnetite Nanoparticles. Male. Middle Aged. Retrospective Studies. Siloxanes. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703865.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Siloxanes; 0 / ferumoxsil; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


61. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
  • Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present.
  • We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


62. Shimizu M, Kawaguchi A, Nagao S, Hozumi H, Komoto S, Hokari R, Miura S, Hatsuse K, Ogata S: A case of intraductal papillary mucinous neoplasm of the pancreas rupturing both the stomach and duodenum. Gastrointest Endosc; 2010 Feb;71(2):406-12
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intraductal papillary mucinous neoplasm of the pancreas rupturing both the stomach and duodenum.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas may extend to other organs.
  • However, it is rare for a histopathologically benign IPMN to rupture other organs, particularly multiple organs.
  • There has been no report of a benign IPMN rupturing both the stomach and duodenum.
  • CONCLUSIONS: We report a case of benign IPMN of the pancreas extending to two adjacent organs.
  • Pathological examinations revealed that the IPMN was composed of adenoma.
  • According to a literature review based on PubMed data up until March 2009, it is rare for a benign IPMN to penetrate two adjacent organs.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Carcinoma, Pancreatic Ductal / secondary. Carcinoma, Papillary / secondary. Duodenal Neoplasms / secondary. Pancreatic Neoplasms / pathology. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922925.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


63. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • SUMMARY BACKGROUND DATA: Pancreatic IPMNs are increasingly recognized, often as incidental findings, especially in people over age 70 and 80.
  • Computed tomography (CT) and magnetic resonance (MR) are unreliable in discriminating a benign from a malignant neoplasm.
  • 18-FDG PET as imaging procedure based on the increased glucose uptake by tumor cells has been suggested for diagnosis and staging of pancreatic cancer.
  • The validation of the diagnosis was made by a surgical procedure (n = 44), a percutaneous biopsy (n = 2), main duct cytology (n = 1), or follow-up (n = 17).
  • Forty-two patients underwent pancreatic resection, 2 palliative surgery, and 20 did not undergo surgery.
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • CONCLUSIONS: 18-FDG PET is more accurate than conventional imaging techniques (CT and MR) in distinguishing benign from malignant (invasive and noninvasive) IPMNs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Alasio TM, Vine A, Sanchez MA, Dardik H: Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature. Ann Diagn Pathol; 2005 Aug;9(4):234-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature.
  • Serous cystadenomas of the pancreas have been classified as benign exocrine tumors.
  • Given the unpredictable metastatic potential of neuroendocrine tumors of the pancreas, we advocate complete resection of all pancreatic cystic tumors, combined with careful sampling of the pathological specimen to rule out a coexistent potentially malignant neoplasm.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084460.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Nanashima A, Takeshita H, Tobinaga S, Araki M, Sumida Y, Kunizaki M, Tanaka K, Abo T, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies. Hepatogastroenterology; 2010 Jul-Aug;57(101):694-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies.
  • To clarify the significance of 1CTP in hepato-biliary pancreas malignancies, we examined the relationship between clinicopathological features and serum level of 1CTP.
  • METHODOLOGY: The subjects were 75 patients who underwent surgical resections including 27 patients with liver carcinomas, 15 with extra-hepatic biliary carcinomas, 14 pancreatic carcinomas and 19 benign diseases.
  • RESULTS: 1CTP level tended to be higher in the malignant diseases than in benign diseases but this difference was not significant (p = 0.065).
  • Compared to benign adenoma, 1CTP level in the malignant diseases was significantly higher (p = 0.049).
  • 1CTP level tended to be higher in patients with cholangitis compared to those with no inflammation or benign tumors (p = 0.065).
  • CONCLUSIONS: Serum level of 1CTP might be a predictive marker for hepatobiliary pancreas malignancies but also reflects the degree of co-existing cholangitis.
  • [MeSH-major] Biliary Tract Neoplasms / pathology. Biomarkers / blood. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / blood. Liver Neoplasms / pathology. Pancreatic Neoplasms / pathology. Peptides / blood

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033212.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


66. Qin X, Liu F: The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas. Front Med China; 2007 May;1(2):121-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas.
  • Since first described in 1982, intraductal papillary mucinous neoplasm (IPMN) has been the preferred term to describe the proliferation of the pancreatic ductal epithelium.
  • It is totally different from pancreatic carcinoma in epidemiology, histology, pathology and prognosis.
  • Most branch duct IPMNs are benign, whereas the other two types are often malignant.
  • A large branch duct IPMN and marked dilation of the main pancreatic duct indicate the presence of adenoma at least.
  • The prognosis is more favorable after complete resection of benign and non-invasive malignant IPMNs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24557662.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Handra-Luca A, Fléjou JF, Rufat P, Corcos O, Belghiti J, Ruszniewski P, Degott C, Bedossa P, Couvelard A: Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology; 2006 Jun;48(7):813-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma.
  • AIMS: To examine cytokeratin, epithelial glycoprotein (mucin) and glycoprotein CD10 expression in benign mucinous cystdenomas (MCAs) in comparison with intraductal papillary mucinous adenomas (IPMAs).
  • METHODS AND RESULTS: Thirty MCAs of the pancreas were analysed for immunohistochemical expression of cytokeratin (CK) 7, CK20, MUC1, MUC2, MUC5AC and CD10 and were compared with 16 IPMAs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-20. Keratins / analysis. Male. Middle Aged. Mucin 5AC. Mucins / analysis. Neprilysin / analysis

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722930.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


68. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary.
  • We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


69. Oku T, Maeda M, Wada Y, Waga E, Ono K, Nagamachi Y, Fujii S, Fujita M, Misu K, Senmaru N, Suzuki Y, Nagashima K, Niitsu Y: Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology. JOP; 2007;8(2):206-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal oncocytic papillary neoplasm having clinical characteristics of mucinous cystic neoplasm and a benign histology.
  • CONTEXT: An intraductal oncocytic papillary neoplasm is a rare pancreatic tumor which was first described by Adsay et al. in 1996.
  • Imaging studies revealed a cystic mass in the body of the pancreas.
  • Microscopically, the cyst was lined by columnar epithelium similar to pancreatic duct epithelium, and the nodular projection consisted of arborizing papillary structures, lined by plump cells with abundant eosinophilic cytoplasm.
  • The cellular atypism was mild and the proliferating index was low, compatible with adenoma of an intraductal oncocytic papillary neoplasm.
  • Although no ovarian type stroma was identified, in our case, no communication to main pancreatic duct (located in the pancreatic body) and rapid growth by intracystic hemorrhage were clinical characteristics of a mucinous cystic neoplasm, but not IPMN.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356245.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


70. Itoh T, Hirooka Y, Itoh A, Hashimoto S, Kawashima H, Hara K, Kanamori A, Ohmiya N, Niwa Y, Goto H: Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol; 2005 Jan;100(1):144-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas.
  • BACKGROUND: The differentiation of benign from malignant intraductal papillary mucinous tumors (IPMT) is often difficult even by various examination methods.
  • We evaluated the qualitative and quantitative diagnostic ability of contrast-enhanced transabdominal ultrasonography (CE-US), mainly in differentiating benign from malignant tumors in patients with IPMT.
  • Pathological findings were 4 with carcinoma and 17 with adenoma.
  • In both the early and late phases, the post-enhancement intensity, difference between pre- and post-enhancement intensity, and the percentage change ((post-enhancement value-pre-enhancement value)/pre-enhancement value) were compared between malignant and benign lesions, and the ability of CE-US to differentiate between benign and malignant lesions was evaluated in comparison with the ability of EUS to diagnose the degree of malignancy. RESULTS:.
  • When the patients with carcinoma were compared with those with adenoma, the post-enhancement intensity was significantly higher, and the difference between pre- and post-enhancement intensity and the percentage change in the early phase and the late phase was significantly more marked in the carcinoma group (p= 0.019, p= 0.002, p= 0.015, p= 0.012, and p= 0.039, respectively).
  • Moreover, quantitative changes in intensity can be a parameter for the differential diagnosis of benign and malignant tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / ultrasonography. Adenocarcinoma, Papillary / ultrasonography. Carcinoma, Pancreatic Ductal / ultrasonography. Contrast Media. Pancreatic Neoplasms / ultrasonography. Polysaccharides

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654794.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


71. Merenda R, Portale G, Galeazzi F, Tosolini C, Sturniolo GC, Ancona E: Pancreaticoduodenectomy for dysplastic duodenal adenoma in a patient with familial adenomatous polyposis. Tumori; 2008 Nov-Dec;94(6):882-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticoduodenectomy for dysplastic duodenal adenoma in a patient with familial adenomatous polyposis.
  • Colorectal polyposis is the main feature of familial adenomatous polyposis (FAP), but benign and malignant lesions have also been described in the stomach, duodenum, small bowel, biliary tract and pancreas.
  • [MeSH-major] Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Colonic Polyps / pathology. Duodenal Neoplasms / surgery. Pancreaticoduodenectomy


72. Fujii T, Ishikawa T, Kanazumi N, Sugimoto H, Nomoto S, Inoue S, Nagasaka T, Takeda S, Nakao A: Analysis of clinicopathological features and predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas. Hepatogastroenterology; 2007 Jan-Feb;54(73):272-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of clinicopathological features and predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
  • RESULTS: The histological diagnosis was adenoma in 40, borderline in 1, carcinoma in situ (CIS) in 7, and invasive carcinoma in 9 patients.
  • Patients with invasive carcinomas had significantly shorter survival rates than patients with benign IPMNs or CIS (p < 0.0001).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419275.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Number-of-references] 32
  •  go-up   go-down


73. Jang JY, Kim SW, Lee SE, Yang SH, Lee KU, Lee YJ, Kim SC, Han DJ, Choi DW, Choi SH, Heo JS, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee HE, Kang GH, Lee JM: Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol; 2008 Jan;15(1):199-205
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe?
  • RESULTS: Of 138 patients (mean age, 60.6 years; 87 men, 51 women), 76 underwent pancreatoduodenectomy, 39 distal pancreatectomy, 4 total pancreatectomy, and 20 limited pancreatic resection.
  • There were 112 benign cases: 47 adenoma, 63 borderline cases, and 26 malignant cases, with 9 of these being noninvasive and 17 invasive.
  • Surgical treatment is recommended, except in cases that are strongly suspected to be benign or cases that present a high operative risk.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909912.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Jang JY, Kim SW, Ahn YJ, Yoon YS, Choi MG, Lee KU, Han JK, Kim WH, Lee YJ, Kim SC, Han DJ, Kim YI, Choi SH, Cho BH, Yu HC, Yoon DS, Lee WJ, Lee KB, Kim YC, Lee KS, Kim MW, Kim HJ, Kim HJ, Park YH: Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol; 2005 Feb;12(2):124-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery?
  • BACKGROUND: Despite recently increasing numbers of reports on intraductal papillary mucinous tumors (IPMTs), difficulties still remain in terms of diagnosis, treatment, and prognosis.
  • A total of 124 patients underwent pancreatoduodenectomy, 42 underwent distal pancreatectomy, 17 underwent total pancreatectomy, and 25 underwent limited pancreatic resection.
  • There were 128 benign cases (adenoma, n = 62; borderline, n = 66) and 80 malignant cases (noninvasive, n = 29; invasive, n = 51).
  • A significant difference in 5-year survival was observed between the benign and malignant groups (92.6% vs. 65.3%; P = .006).
  • Of the six factors (age, location, duct dilatation, mural nodule, main duct type, and tumor size) that showed statistical differences by univariate analysis between the benign and malignant groups, three were significant by multivariate analysis--namely, mural nodule (P = .009), tumor size (P = .023), and a dilated duct size (P = .010).
  • CONCLUSIONS: A significant proportion of IPMTs are malignant, although the overall prognosis of IPMT is superior to that of ordinary pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):98-9 [15827786.001]
  • (PMID = 15827792.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


75. Hirano S, Kondo S, Tanaka E, Shichinohe T, Suzuki O, Shimizu M, Itoh T: Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas. Hepatogastroenterology; 2009 Mar-Apr;56(90):515-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas.
  • BACKGROUND/AIMS: This retrospective study evaluated the suitability of computed tomography (CT) to detect malignancy while following patients with branch-type IPMN, most of which are benign and may be treated with observation alone.
  • METHODOLOGY: Forty-two surgical specimens resected from patients with a diagnosis of branch-type IPMN were pathologically classified as benign (n=26), which included hyperplasia and adenoma, or malignant (n=16), including moderate dysplasia or adenocarcinoma.
  • It was compared the differences in the sizes of the tumor and main pancreatic duct (MPD) and the presence of mural nodules on CT between the groups.
  • RESULTS: In the malignant group, it was observed a larger tumor size (47.8 vs. 23.8 mm; p = 0.001) and increased dilation of the MPD (9.3 vs. 5.0 mm; p = 0.001) than those seen in the benign group.
  • The accuracy of CT diagnosis of mural nodules, however, was only 62%.
  • Increases in these morphological characteristics on CT images during the follow-up period would be an accurate method to predict a diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Papillary / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579633.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


76. Linder JD, Geenen JE, Catalano MF: Cyst fluid analysis obtained by EUS-guided FNA in the evaluation of discrete cystic neoplasms of the pancreas: a prospective single-center experience. Gastrointest Endosc; 2006 Nov;64(5):697-702
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyst fluid analysis obtained by EUS-guided FNA in the evaluation of discrete cystic neoplasms of the pancreas: a prospective single-center experience.
  • BACKGROUND: Accurate assessment of pancreatic cystic neoplasms is imperative before selecting available treatment options, such as surgical resection, drainage, or conservative therapy.
  • Available modalities, CT and magnetic resonance imaging, have been inconsistent in diagnosis.
  • Reports involving EUS and cyst fluid analysis have been encouraging, including studies of EUS features and/or cyst fluid analysis, which may differentiate pancreatic cystic neoplasms.
  • SETTING: Pancreatic Biliary Center, St Luke's Medical Center, Milwaukee, Wisconsin.
  • PATIENTS: A total of 102 patients (60 women, 42 men; age, 23-76 years) presented for evaluation of pancreatic cystic neoplasm; 71 underwent surgical resection.
  • The CEA level was significantly higher in MCyA (adenoma [878 ng/mL], carcinoma [27,581 ng/mL]) vs PC (189 ng/mL), and SCyA (121 ng/mL).
  • CONCLUSIONS: Differential diagnosis of pancreatic cystic neoplasm is significantly enhanced by cyst fluid analysis.
  • Malignant from benign MCN can be differentiated by CEA levels > or =6000 ng/mL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle / methods. Cyst Fluid / chemistry. Endosonography. Pancreatic Neoplasms / chemistry. Pancreatic Pseudocyst / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2006 Nov;64(5):703-4 [17055860.001]
  • (PMID = 17055859.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucins; EC 3.1.1.3 / Lipase; EC 3.2.1.- / Amylases
  •  go-up   go-down


77. Böttger T, Terzic A, Müller M: [Laparoscopic pancreatic resection]. Zentralbl Chir; 2006 Aug;131(4):309-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic pancreatic resection].
  • Over a long time laparascopy for pancreatic diseases was performed only as staging laparoscopy in order to find hidden metastasis.
  • Laparoscopic distal resection of pancreas is much more feasible due to lack of intestinal anastomoses.
  • Anyway there is only few literature about laparoscopic left pancreatic resection found.
  • RESULTS: In all four cases laparoscopic distal pancreatic resection was performed for tumor.
  • Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous tumor of borderline type.
  • CONCLUSION: Laparoscopic resection of distal pancreas shows the common benefit of minimal invasive surgery for the early postoperative period and is an attractive alternative for treatment of benign and semimalign pancreatic tumors.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004190.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Shah OJ, Robbani I, Nazir P, Khan AB: Central pancreatectomy: a new technique for resection of selected pancreatic tumors. Hepatobiliary Pancreat Dis Int; 2009 Feb;8(1):93-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pancreatectomy: a new technique for resection of selected pancreatic tumors.
  • BACKGROUND: Pancreatic tumors located in the neck region usually require pancreaticoduodenectomy or splenopancreatectomy.
  • For small benign tumors enucleation is not usually feasible due to their size and localization; then pancreatectomy is often needed.
  • Central pancreatectomy consists of a limited resection of the midportion of the pancreas and can be offered in benign and low-grade malignant tumors of the neck of the pancreas.
  • The study aimed to evaluate whether central pancreatectomy has a place in pancreatic surgery.
  • CONCLUSIONS: Central pancreatectomy is a procedure that offers excellent results in benign and low-grade malignant tumors.
  • It preserves functional elements (endocrine and exocrine) of the pancreas and also eliminates the infective and hematological effects of splenectomy.
  • Thus, central pancreatectomy should be included in the armamentarium of pancreatic surgery, and in order to obtain good results, proper indications and adequate experience are recommended.
  • [MeSH-major] Cystadenoma / surgery. Echinococcosis / surgery. Pancreas / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / surgery. Adult. Biopsy. Female. Follow-Up Studies. Humans. Male. Postoperative Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208523.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  •  go-up   go-down


79. Gonzalvez Gasch AM, Mirete Ferrer C, Laveda Cano R, Satorres Rosas J: A case of a solid renal mass together with a cystic pancreatic lesion in a 50-year-old patient. JOP; 2005 Mar;6(2):172-7
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a solid renal mass together with a cystic pancreatic lesion in a 50-year-old patient.
  • CONTEXT: Pancreatic cysts may be incidentally detected in asymptomatic patients evaluated for other clinical manifestations.
  • Microcystic adenomas are particularly rare among pancreatic cyst neoplasms.
  • They are benign lesions and can present as solitary pancreatic tumors or as a radiological manifestation combined with other cystic and tumoral lesions affecting different organs.
  • A computed tomography scan of the abdomen showed a 9-centimeter renal mass in the left kidney consistent with a renal-cell carcinoma as well as a cystic lesion the head of the pancreas.
  • The histopathological study of the cystic mass, following a computed tomography guided biopsy, showed a microcystic adenoma.
  • Therefore, further studies were performed so as to assess the relationship between both lesions and determine the final diagnosis.
  • CONCLUSIONS: Microcystic adenomas are exceedingly rare tumors among pancreatic cysts.
  • The combination of a solid renal mass and a pancreatic cystic lesion should lead to a broad differential diagnosis.
  • Pancreatic magnetic resonance imaging has been proven to be particularly useful in evaluating cystic masses.
  • The presence of walls and internal septations in the pancreatic mass with gadolinium enhancement should raise the possibility of an underlying Von Hippel-Lindau syndrome.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. von Hippel-Lindau Disease / diagnosis
  • [MeSH-minor] Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / pathology. Diagnosis, Differential. Hemangioblastoma / complications. Hemangioblastoma / diagnosis. Hemangioblastoma / pathology. Hematuria / diagnosis. Hematuria / etiology. Hematuria / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767734.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


80. Beger HG, Rau BM, Gansauge F, Schwarz M, Siech M, Poch B: Duodenum-preserving total pancreatic head resection for cystic neoplasm: a limited but cancer-preventive procedure. Langenbecks Arch Surg; 2008 Jul;393(4):589-98
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-preserving total pancreatic head resection for cystic neoplasm: a limited but cancer-preventive procedure.
  • BACKGROUND: Cystic neoplastic lesions of the pancreas are found in up to 10% of all pancreatic lesions.
  • For cystic neoplasia located monocentrically in the pancreatic head and that do not have an association with an invasive pancreatic cancer, the duodenum-preserving total head resection has been used in recent time as a limited surgical procedure.
  • PATIENTS: An indication to duodenum-preserving total pancreatic head resection is considered for patients who do not have clinical signs of an advanced cancer in the lesion and who have main-duct IPMN and monocentric MCN lesions.
  • In 104 patients with cystic neoplastic lesions in the Ulm series, 32% finally had a carcinoma in situ or an advanced pancreatic cancer.
  • The application of a duodenum-preserving total pancreatic head resection in patients with asymptomatic cystic lesion is based on the size of the tumor and the tumor relation to the pancreatic ducts.
  • RESULTS: Duodenum-preserving total pancreatic head resection is used in several modifications.
  • The surgical procedure is a limited pancreatic head resection which necessitates segmental resection of the peripapillary duodenum.
  • The long-term outcome is determined by completeness of resection for both -- benign and malignant -- entities.
  • CONCLUSION: A duodenum-preserving total pancreatic head resection is a limited surgical procedure for patients who suffer a local monocentric, cystic neoplastic lesion in the pancreatic head.
  • Absence of an advanced pancreatic cancer and completeness of extirpation of the benign tumor determine the long-term outcome.
  • In regards to the location of the lesion in the pancreatic head, several modifications have been applied with low hospital morbidity and mortality below 1%.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379818.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Arkadopoulos N, Karapanos K, Stafyla V, Yiallourou A, Koureas A, Kondi-Pafiti A, Smyrniotis V: Combination of right nephrectomy and total pancreaticoduodenectomy for Von Hippel-Lindau disease. JOP; 2010;11(3):270-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Von Hippel-Lindau disease is an inherited syndrome of multiorgan neoplasia caused by a germline mutation in the von Hippel-Lindau gene and can include central nervous system tumors, renal cell carcinomas and benign pancreatic cystic tumors.
  • Imaging revealed renal tumors and multiple pancreatic tumors which caused duodenal and pancreatic duct compression.
  • Pathology identified a multifocal unilateral clear cell renal carcinoma which interestingly coexisted with multiple large pancreatic serous microcystic adenomas with infiltration of the fibrous capsule.
  • CONCLUSION: In past cases of von Hippel-Lindau disease, pancreatic adenomas with malignant transformation have not been reported.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Neoplasms, Multiple Primary / surgery. Nephrectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / radiography. Adenoma / surgery. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Splenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442526.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


82. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology; 2007 Jul;133(1):72-9; quiz 309-10
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in branch ducts are thought to be less aggressive than their main-duct counterparts, and guidelines for their conservative management were recently proposed.
  • RESULTS: Sixty-six patients (45.5%) had adenoma, 47 (32%) borderline tumors, 16 (11%) carcinoma in situ, and 16 (11%) invasive carcinoma.
  • Median age was similar between benign and malignant subgroups (66 vs 67.5 years, respectively).
  • Jaundice was more frequent in patients with cancer (12.5% vs 1.8%, respectively, P = .022) and abdominal pain in patients with benign tumors (45% vs 25%, respectively, P = .025).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality. Practice Guidelines as Topic / standards. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):98-9 [15827786.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4518-23 [16002842.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):669-75 [16082582.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):91-3 [16847916.001]
  • [Cites] Clin Radiol. 2006 Sep;61(9):776-83 [16905386.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):323-37; discussion 337-40 [11259696.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [CommentIn] Gastroenterology. 2007 Jul;133(1):345-50 [17631154.001]
  • (PMID = 17631133.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS519078; NLM/ PMC3807096
  •  go-up   go-down


83. Christein JD, Smoot RL, Farnell MB: Central pancreatectomy: a technique for the resection of pancreatic neck lesions. Arch Surg; 2006 Mar;141(3):293-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pancreatectomy: a technique for the resection of pancreatic neck lesions.
  • Although historically used for traumatic pancreatic transection and chronic pancreatitis, it currently is reserved for selective management of pancreatic neck lesions that are benign or have low malignant potential.
  • Our objectives were to describe the technique and determine the safety and effectiveness of central pancreatectomy in the excision of benign or low-malignant potential lesions of the pancreatic neck.
  • INTERVENTION: Patients with pancreatic neck or proximal body masses underwent central pancreatectomy at the Mayo Clinic, Rochester, Minn.
  • The most common complication was pancreatic leak (5 patients [63%]).
  • One patient transiently required oral pancreatic enzyme supplementation.
  • The most common complication is pancreatic leak.
  • Caution is necessary when using central pancreatectomy in the treatment of pancreatic neck lesions.
  • The precise role of central pancreatectomy in the management of benign or low-malignant potential lesions of the neck of the pancreas remains in evolution.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / radiography. Adenoma, Islet Cell / surgery. Cystadenoma, Serous / radiography. Cystadenoma, Serous / surgery. Female. Humans. Liposarcoma / surgery. Male. Mesenteric Veins / surgery. Middle Aged. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549696.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Ge D, You Z: Expression of interleukin-17RC protein in normal human tissues. Int Arch Med; 2008;1(1):19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: IL-17RC expression in 51 normal human tissues and two benign tumors (i.e., lymphangioma and parathyroid adenoma) on the tissue microarrays was determined by immunohistochemical staining, using two polyclonal antibodies against IL-17RC.
  • IL-17RC protein was expressed in many cell types including the myocardial cells, vascular and lymphatic endothelial cells, glandular cells (of the adrenal, parathyroid, pituitary, thyroid, pancreas, parotid salivary, and subepidermal glands), epithelial cells (of the esophagus, stomach, intestine, anus, renal tubule, breast, cervix, Fallopian tube, epididymis, seminal vesicle, prostate, gallbladder, bronchus, lung, and skin), oocytes in the ovary, Sertoli cells in the testis, motor neurons in the spinal cord, autonomic ganglia and nerves in the intestine, skeletal muscle cells, adipocytes, articular chondrocytes, and synovial cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2078-87 [18310510.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1207-11 [18200064.001]
  • [Cites] Cytokine. 2008 Feb;41(2):92-104 [18178098.001]
  • [Cites] Cytokine. 2008 Feb;41(2):105-13 [18061473.001]
  • [Cites] Cytokine. 2008 Feb;41(2):84-91 [18039580.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):597-607 [18202747.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):124-6 [18204425.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):655-63 [18097068.001]
  • [Cites] Cytokine. 2007 Oct;40(1):35-43 [17881243.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5462-73 [17911633.001]
  • [Cites] Cytokine. 2007 Jun;38(3):157-64 [17644350.001]
  • [Cites] J Heart Lung Transplant. 2007 Jul;26(7):669-74 [17613395.001]
  • [Cites] Neoplasia. 2007 Jun;9(6):464-70 [17603628.001]
  • [Cites] Cell Res. 2007 May;17(5):435-40 [17452998.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13447-55 [17355969.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4466-72 [17372004.001]
  • [Cites] J Neuroimmunol. 2007 Feb;183(1-2):96-103 [17240458.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1372-8 [17237384.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8542-9 [17142752.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6852-8 [17082599.001]
  • [Cites] Prostate. 2006 Sep 1;66(12):1268-74 [16688746.001]
  • [Cites] J Neurosci Res. 2006 Aug 1;84(2):379-88 [16676327.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):566-73 [16785554.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):36-9 [16785495.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1685-91 [16818675.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1287-98 [16310341.001]
  • [Cites] Cell Immunol. 2005 Oct;237(2):123-30 [16386239.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):175-83 [16397230.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):711-5 [16393951.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Sep;33(3):248-53 [15901616.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):404-12 [15972674.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):560-6 [15799031.001]
  • [Cites] Immunity. 2005 Mar;22(3):285-94 [15780986.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):233-40 [15657292.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 21;326(3):624-31 [15596145.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8276-84 [15548695.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3698-704 [10446984.001]
  • [Cites] J Immunol. 1999 Jan 1;162(1):577-84 [9886435.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5483-6 [7499828.001]
  • [Cites] Immunity. 1995 Dec;3(6):811-21 [8777726.001]
  • [Cites] Immunity. 2004 Oct;21(4):467-76 [15485625.001]
  • [Cites] Joint Bone Spine. 2004 Mar;71(2):87-90 [15050191.001]
  • [Cites] Cell Mol Life Sci. 2004 Mar;61(5):567-79 [15004696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1229-34 [14742870.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50273-82 [12958313.001]
  • [Cites] Br J Pharmacol. 2003 Oct;140(4):595-610 [14504135.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33232-8 [12807873.001]
  • [Cites] Prostate. 2003 Aug 1;56(3):171-82 [12772186.001]
  • [Cites] Scand J Gastroenterol. 2003 Feb;38(2):180-5 [12678335.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Apr;14(2):155-74 [12651226.001]
  • [Cites] Gut. 2003 Jan;52(1):65-70 [12477762.001]
  • [Cites] Nat Med. 2002 May;8(5):500-8 [11984595.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4309-16 [11706037.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):170-4 [11802165.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):165-9 [11802164.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):861-8 [11777983.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6015-20 [11698482.001]
  • [Cites] Transplant Proc. 2000 Nov;32(7):1773 [11119928.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1660-4 [11058597.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19167-76 [10749887.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2799-805 [18684971.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1063-75 [18411338.001]
  • (PMID = 18928529.001).
  • [ISSN] 1755-7682
  • [Journal-full-title] International archives of medicine
  • [ISO-abbreviation] Int Arch Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2596096
  •  go-up   go-down


85. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • The slides were evaluated in a blinded fashion, and the results were compared between the benign and malignant lesions.
  • Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0%; mCEA, 0%; HER2/neu, 12%; mesothelin, 0%; loss of Dpc4, 0%) or BDH (CK20, 10%; p53, 0%; TAG-72, 0%; mCEA, 10%; HER2/neu, 0%; mesothelin, 0%; loss of Dpc4, 0%).
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • Although none of the BDA or BDH was positive for either p63 or AMACR, two of the metastatic pancreatic adenocarcinomas (8%) were positive for each of these peptides (P > 0.05).
  • For nonpancreatic adenocarcinomas, mCEA showed a reasonably high sensitivity and 100% specificity in the differential diagnosis versus BDA.
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques


86. Gumbs AA, Grès P, Madureira F, Gayet B: Laparoscopic vs open resection of pancreatic endocrine neoplasms: single institution's experience over 14 years. Langenbecks Arch Surg; 2008 May;393(3):391-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic vs open resection of pancreatic endocrine neoplasms: single institution's experience over 14 years.
  • BACKGROUND: Laparoscopic resection of benign pancreatic endocrine neoplasms (PENs) has become the standard of care for tumors in the pancreatic tail.
  • Over a 14-year period, we have resected both benign and malignant tumors of the entire pancreas laparoscopically and compared our survival and complication rates with open controls.
  • CONCLUSIONS: Laparoscopic resection of benign and malignant PENs has similar overall complication and 5-year survival rates as the open technique; however, the laparoscopic approach is associated with shorter operative times.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196267.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


87. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • There were 6 cases of neuroendocrine tumours localized in pancreas.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Hisa T, Ohkubo H, Shiozawa S, Ishigame H, Takamatsu M, Furutake M, Nobukawa B, Suda K: Growth process of small pancreatic carcinoma: a case report with imaging observation for 22 months. World J Gastroenterol; 2008 Mar 28;14(12):1958-60
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth process of small pancreatic carcinoma: a case report with imaging observation for 22 months.
  • This report describes serial observations of the growth process of a small invasive ductal carcinoma (IDC) of the pancreas from imaging studies.
  • Histopathological studies showed IDC with macroscopic retention cysts proximal to an intraductal papillary-mucinous adenoma with mild atypia of the branch duct type in the pancreatic body, with no relation between the two lesions.
  • We misinterpreted the low-echoic mass as a benign intraductal mucinous-papillary neoplasm (IPMN) based on findings of other imaging studies, and the patient was followed-up.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Carcinoma, Pancreatic Ductal / ultrasonography. Pancreatic Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2001 May;22(4):366-9 [11345136.001]
  • [Cites] Pancreatology. 2002;2(4):407-12 [12138230.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):42-6 [9448015.001]
  • [Cites] Abdom Imaging. 1998 Jul-Aug;23(4):380-6 [9663273.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):610-1 [15812422.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 May;91(5):1003-15 [8196194.001]
  • (PMID = 18350642.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2700420
  •  go-up   go-down


89. Singh A, Pandey KC, Pant NK: Cavitary mucoepidermoid carcinoma of lung with metastases in skeletal muscles as presenting features: a case report and review of the literature. J Cancer Res Ther; 2010 Jul-Sep;6(3):350-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Later studies showed that they can arise as a primary in bronchus, esophagus, lacrimal glands, pancreas, thymus and thyroid gland.
  • Initially described as a benign adenoma, it is now considered to be a malignant epithelial tumor.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Lung Neoplasms / diagnosis. Muscle Neoplasms / secondary. Muscle, Skeletal / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119274.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


90. Shimamoto T, Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, Shimizu A, Uchiyama K, Yokoyama S, Tsutsumi M, Yamaue H: MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography. Pancreas; 2010 Aug;39(6):879-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography.
  • OBJECTIVES: Some intraductal papillary mucinous neoplasms (IPMNs) have no proliferation to malignant IPMNs, and benign IPMNs can observe the natural course without a surgical intervention.
  • METHODS: Quantitative real-time reverse transcription-polymerase chain reaction was performed for pancreatic juice by a LightCycler instrument focused on carcinoembryonic antigen, MUC1, and human telomerase reverse transcriptase.
  • RESULTS: MUC1/glyceraldehyde-3-phosphate dehydrogenase messenger RNA (mRNA) ratio in intraductal papillary mucinous carcinoma (IPMC; median, 4710.7) was significantly higher in intraductal papillary mucinous adenoma (IPMA; median, 727; P = 0.0229).
  • CONCLUSIONS: Quantitative reverse transcription-polymerase chain reaction using MUC1 is useful for the detection of malignant IPMN in pure pancreatic juice.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Papillary / genetics. Mucin-1 / genetics. Pancreatic Juice / metabolism. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357691.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


91. Li FY, Ren XB, Xu EP, Huang Q, Sheng HQ, Lv BJ, Lai MD: RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor. J Zhejiang Univ Sci B; 2010 Apr;11(4):258-66
Genetic Alliance. consumer health - Pancreatic islet cell tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating gene IV (RegIV), a member of the regenerating gene family discovered in 2001, has been found to be involved in malignancy in several different organs including the stomach, colorectum, pancreas and prostate, but the overall expression profile of RegIV has not been reported.
  • To learn more about RegIV, we evaluated its distribution by immunohistochemistry (IHC) in a total of 360 samples including 24 types of normal tissue, 40 benign and malignant lesions, and 18 neuroendocrine tumors.
  • Studies on additional sets of colorectal tumor samples showed that RegIV expression was predominant in colorectal adenoma (87.5%) and peritumoral tissue (100%) but not in cancer tissue (30.8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Feb;13(2):140-6 [10697270.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):59-69 [19740514.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 16;1518(3):287-93 [11311942.001]
  • [Cites] Diabetes. 2002 Feb;51(2):339-46 [11812740.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):185-93 [12455032.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):11-20 [12819006.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):69-76 [14550954.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):963-9 [14559978.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2635-41 [14669303.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1130-6 [15022278.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] J Am Coll Surg. 1994 Aug;179(2):231-48 [8044398.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2237-43 [15788672.001]
  • [Cites] J Pathol. 2005 Oct;207(2):185-98 [16086444.001]
  • [Cites] Gut. 2005 Oct;54(10):1437-44 [15914572.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):137-49 [16401477.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1191-7 [16918991.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1714-20 [17106246.001]
  • [Cites] Lab Invest. 2007 Mar;87(3):304-14 [17260007.001]
  • [Cites] Oncology. 2007;72(5-6):371-80 [18187959.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [ErratumIn] J Zhejiang Univ Sci B. 2010 May;11(5):390
  • (PMID = 20349522.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / REG4 protein, human
  • [Other-IDs] NLM/ PMC2852542
  •  go-up   go-down


92. Ridolfini MP, Gourgiotis S, Alfieri S, Di Miceli D, Rotondi F, Limongelli F, Quero G, Larghi A, Cazzato MT, Martella N, Doglietto GB: [Presentation, treatment and prognosis of intraductal papillary mucinous neoplasm]. Ann Ital Chir; 2007 Jul-Aug;78(4):257-64
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMNs) are rare tumours rising from the pancreatic duct epithelium.
  • They are characterized by intraductal papillary growth and thick mucin secretion; mucin fills the Wirsung and/or branch pancreatic ducts and may cause ductal dilatation.
  • Most branch type IPMNs are benign, while the other two types are frequently malignant.
  • Recent advances in diagnostic imaging have led to an increased frequency of diagnosis of IPMNs, but the clinical features of them can range broadly from benign, borderline, and malignant non-invasive to invasive lesions, and their management has not yet been clearly defined.
  • Presence of a large branch type IPMN and marked dilatation of the main duct indicate the existence of adenoma.
  • Endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography (EUS), intraductal ultrasonography, and magnetic resonance cholangiopancreatography (MRCP) are the most valuable imaging techniques for diagnosis of these lesions.
  • Prognosis is excellent after complete resection of benign and non-invasive malignant IPMNs.
  • Total pancreatectomy should be reserved for patients with resectable but extensive IPMN involving the whole pancreas; its benefits must be balanced against perioperative risks.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Diagnosis, Differential. Dilatation, Pathologic / etiology. Female. Humans. Male. Middle Aged. Pancreatic Ducts. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990599.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 75
  •  go-up   go-down


93. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer; 2005 Jan 17;92(1):94-101
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
  • The aim of this study is to evaluate angiogenesis and expression of HIF-related molecules in a series of patients with pancreatic endocrine tumours (PETs).
  • Microvascular density was significantly higher in benign PETs than in PETs of uncertain prognosis, well-differentiated and poorly differentiated carcinomas (mean values: 535, 436, 252 and 45 vessels mm(-2), respectively, P < 0.0001).
  • The regulation of HIF signalling appears to be specific in pancreatic endocrine tumours.
  • [MeSH-major] Adenoma, Islet Cell / blood supply. Adenoma, Islet Cell / metabolism. Neovascularization, Pathologic. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / metabolism. Vascular Endothelial Growth Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Apr;34(5):609-18 [9713263.001]
  • [Cites] Neuroendocrinology. 1986;43(2):159-65 [3523276.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1309-16 [9815813.001]
  • [Cites] J Pathol. 1998 Nov;186(3):313-8 [10211122.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1388-93 [10728704.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1441-5 [10780524.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):167-71 [11248550.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Nature. 2001 Aug 30;412(6850):877-84 [11528470.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):177-81 [11550286.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):881-90 [11556841.001]
  • [Cites] Novartis Found Symp. 2001;240:212-25; discussion 225-31 [11727931.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):719-25 [11857345.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1276-82 [11953885.001]
  • [Cites] Semin Cell Dev Biol. 2002 Feb;13(1):29-37 [11969369.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2595-604 [12171890.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):45-53; discussion 54 [12210027.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4961-5 [12414859.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):181-5 [12539172.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):18-27 [12605362.001]
  • [Cites] Histopathology. 2003 May;42(5):482-91 [12713626.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):319-23 [7543771.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1196-200 [7590692.001]
  • [Cites] Mol Endocrinol. 1995 Dec;9(12):1760-70 [8614412.001]
  • [Cites] Genomics. 1996 May 1;33(3):480-7 [8661007.001]
  • [Cites] Histopathology. 1997 Mar;30(3):294-301 [9088964.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1417-23 [9358768.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):286-93 [9495200.001]
  • [Cites] Histopathology. 1998 Feb;32(2):133-8 [9543669.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):329-33 [9578082.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Gastroenterology. 2003 Oct;125(4):1094-104 [14517793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • (PMID = 15558070.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factors; 0 / endothelial PAS domain-containing protein 1; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2361752
  •  go-up   go-down


94. Blandamura S, Parenti A, Famengo B, Canesso A, Moschino P, Pasquali C, Pizzi S, Guzzardo V, Ninfo V: Three cases of pancreatic serous cystadenoma and endocrine tumour. J Clin Pathol; 2007 Mar;60(3):278-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of pancreatic serous cystadenoma and endocrine tumour.
  • AIMS: To report three cases of serous cystadenoma and endocrine tumour in the same pancreas, to review the literature and to evaluate the clinicopathological features of the tumours.
  • CASES: Three women (71, 57 and 31 years old) were admitted to hospital, two for diseases unrelated to the pancreas and the third for increasing obstructive jaundice in von Hippel-Lindau disease.
  • RESULTS: Histological examination of the pancreas showed one serous oligocystic adenoma associated with a benign, well-differentiated endocrine tumour, one serous oligocystic adenoma associated with an endocrine microadenoma, and a von Hippel-Lindau-related cystic neoplasm with a well-differentiated endocrine carcinoma.
  • [MeSH-major] Cystadenoma, Serous / pathology. Endocrine Gland Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2000 Jan;73(865):83-6 [10721327.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):800-2 [11064680.001]
  • [Cites] J Histochem Cytochem. 2000 Dec;48(12):1667-76 [11101635.001]
  • [Cites] Surgery. 2000 Dec;128(6):1022-7;discussion 1027-8 [11114638.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1369-72 [14521452.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1934-8 [15070966.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Arch Pathol. 1971 Jul;92(1):28-30 [5091592.001]
  • [Cites] Virchows Arch B Cell Pathol. 1974;17(1):13-27 [4217036.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):185-90 [6258500.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]
  • [Cites] Gastroenterology. 1987 Jun;92(6):1934-43 [3471621.001]
  • [Cites] Am J Surg Pathol. 1988 Apr;12(4):251-63 [3354751.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):161-72 [1748829.001]
  • [Cites] Cancer. 1992 May 15;69(10):2449-53 [1568167.001]
  • [Cites] Gastroenterol Clin Biol. 1993;17(12):968-71 [8125232.001]
  • [Cites] Virchows Arch. 1994;424(1):13-7 [7526946.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):471-5 [8604814.001]
  • [Cites] J Korean Med Sci. 1997 Oct;12(5):469-72 [9364309.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Arch Pathol. 1962 Nov;74:439-52 [13931023.001]
  • [Cites] Ann Diagn Pathol. 2005 Aug;9(4):234-8 [16084460.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):1087-95 [11040195.001]
  • (PMID = 16644876.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1860571
  •  go-up   go-down


95. Long KB, Srivastava A, Hirsch MS, Hornick JL: PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol; 2010 May;34(5):723-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
  • In the pancreas, PAX proteins play a critical role in islet cell differentiation.
  • However, PAX8 expression has not previously been examined in pancreatic endocrine tumors (PETs).
  • Expression of PAX8 was significantly associated with WHO category 1.1 ("benign" behavior) compared with category 1.2 (uncertain behavior) or 2 (well-differentiated endocrine carcinoma) (positive in 100%, 64%, and 52% of tumors, respectively; P<0.05).
  • In summary, PAX8 is expressed in normal pancreatic islet cells and in a high proportion of primary and metastatic PETs.
  • PAX8 immunostaining may be helpful in determining the primary site for a WDNET metastatic to the liver, as ileal (PAX8 negative) and pancreatic (PAX8 positive) tumors most often present as a metastasis from an occult primary.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoid Tumor / pathology. Carcinoma, Islet Cell / secondary. Gastrointestinal Neoplasms / pathology. Lung Neoplasms / pathology. Paired Box Transcription Factors / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Dec;35(12):1906-8 [22067332.001]
  • (PMID = 20414099.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


96. Sasaki A, Nitta H, Nakajima J, Obuchi T, Baba S, Wakabayashi G: Laparoscopic spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein: report of three cases. Surg Today; 2008;38(10):955-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between March 2003 and March 2007, three patients with benign pancreatic tumors underwent a planned laparoscopic spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein.
  • Four trocars were placed, and an endoscopic linear stapler was used to transect of the pancreas.
  • The postoperative pathological diagnoses included one insulinoma, one solid pseudopapillary tumor, and one intraductal papillary-mucinous adenoma.
  • A laparoscopic spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein is a safe and feasible treatment option without compromising the splenic function for benign or borderline malignant tumors in the distal pancreas.
  • [MeSH-major] Laparoscopy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Spleen / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820875.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Basturk O, Coban I, Adsay NV: Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med; 2009 Mar;133(3):423-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications.
  • CONTEXT: Cystic lesions of the pancreas are being recognized with increasing frequency and have become a more common finding in clinical practice because of the widespread use of advanced imaging modalities and the sharp drop in the mortality rate of pancreatic surgery.
  • Consequently, in the past 2 decades, the nature of many cystic tumors in this organ has been better characterized, and significant developments have taken place in the classification and in our understanding of pancreatic cystic lesions.
  • OBJECTIVE: To provide an overview of the current concepts in classification, differential diagnosis, and clinical/biologic behavior of pancreatic cystic tumors.
  • CONCLUSIONS: In contrast to solid tumors, most of which are invasive ductal adenocarcinomas with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • However, those that are mucinous, namely, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, constitute an important category because they have well-established malignant potential, representing an adenoma-carcinoma sequence.
  • Those that are nonmucinous such as serous tumors, congenital cysts, lymphoepithelial cysts, and squamoid cyst of pancreatic ducts have no malignant potential.
  • Only rare nonmucinous cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia, such as cystic ductal adenocarcinomas, cystic pancreatic endocrine neoplasia, and solid-pseudopapillary neoplasm, are also malignant and have variable degrees of aggressiveness.
  • [MeSH-major] Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / diagnosis. Pancreatic Pseudocyst / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260748.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 204
  •  go-up   go-down


98. Krysiak R, Okopień B, Herman ZS: [Insulinoma]. Pol Merkur Lekarski; 2007 Jan;22(127):70-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinoma is considered the most common endocrine tumour of the pancreas with an annual prevalence of 4 cases per million people.
  • Contrary to the other endocrine tumours of this organ, over 90% of the insulinomas are benign in nature.
  • Effective management requires directed biochemical testing, careful choice of preoperative imaging tests, and complete pancreatic exploration by an experienced endocrine surgeon utilising intraoperative ultrasound.
  • The aim of this paper is to critically discuss contemporary diagnosis and treatment of this neoplasm on the basis of progress made in recent years.
  • [MeSH-major] Adenoma, Islet Cell / complications. Adenoma, Islet Cell / diagnosis. Insulinoma / complications. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endocrine Surgical Procedures / methods. Gastrinoma / complications. Gastrinoma / diagnosis. Gastrinoma / metabolism. Gastrinoma / surgery. Humans. Hypoglycemia / complications. Insulin / metabolism. Pancreatectomy / methods. Prognosis. Rare Diseases

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477096.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Insulin
  • [Number-of-references] 34
  •  go-up   go-down


99. Cheng CL, Fogel EL, Sherman S, McHenry L, Watkins JL, Croffie JM, Gupta SK, Fitzgerald JF, Lazzell-Pannell L, Schmidt S, Lehman GA: Diagnostic and therapeutic endoscopic retrograde cholangiopancreatography in children: a large series report. J Pediatr Gastroenterol Nutr; 2005 Oct;41(4):445-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications included biliary pathology (n = 93), pancreatic pathology (n = 111), and chronic abdominal pain of suspected biliary or pancreatic origin (n = 41).
  • The ERCP findings were bile duct stone(s) (n = 29), benign biliary stricture (n = 19), primary sclerosing cholangitis (n = 7), anomalous pancreaticobiliary union (n = 8), choledochal cyst (n = 5), bile duct leak (n = 6), malignant biliary stricture (n = 2), biliary atresia (n = 1), chronic pancreatitis (n = 44), pancreas divisum (n = 26), pancreatic duct stricture with (n = 6) or without (n = 9) leak, pancreatic tumor (n = 1), periampullary adenoma (n = 2), and sphincter of Oddi dysfunction (n = 65).
  • [MeSH-major] Biliary Tract Diseases / diagnosis. Biliary Tract Diseases / therapy. Cholangiopancreatography, Endoscopic Retrograde. Pancreatic Diseases / diagnosis. Pancreatic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205513.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Paik WH, Yoon YB, Lee SH, Park JK, Woo SM, Yang KY, Seo JK, Ryu JK, Kim YT: [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival]. Korean J Gastroenterol; 2008 Sep;52(3):171-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival].
  • BACKGROUND/AIMS: Since pancreatic endocrine tumors (PET) are rare and heterogeneous diseases, their survival and prognosis are not well known.
  • Due to recent advances in CT/MRI technology, incidentalomas of the pancreas are detected with increasing frequency.
  • Overall 5-year survival rate was 68.1%, and 5-year survival rate of the patients who had distant metastases at initial diagnosis was 43.9%.
  • CONCLUSIONS: Because small and pathologically benign nature do not predict good prognosis in PET, aggressive treatment such as curative resection would be considered initially even in the case of incidental PET.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / mortality. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077513.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down






Advertisement